Entries |
Document | Title | Date |
20080213293 | Prevention and Treatment of Recurrent Respiratory Papillomatosis - Juvenile-onset recurrent respiratory papillomatosis is treated using active vaccination or passive immune therapy of neutralizing antibodies against HPV L2 neutralizing epitopes. | 09-04-2008 |
20080226666 | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof - The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones. | 09-18-2008 |
20080233141 | Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection - This invention provides compositions including a chimera of papillomavirus capsid polypeptide L2 and polypeptide including an immunotherapeutic epitope, and GST fusions thereof. The present invention also provides complexes comprising chimeras of papillomavirus L2 polypeptides non-covalently associated with papillomavirus L1 polypeptides, and GST fusions thereof. These compositions may be used to elicit immune responses in a patient to papillomavirus. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infection, especially papillomavirus infection and cervical cancers and warts associated therewith, made from compositions of this invention, are also disclosed. Nucleic acids and expression vectors coding for compositions of this invention are also disclosed. | 09-25-2008 |
20080241179 | Structural proteins of fish pancreatic disease virus and uses thereof - The present invention relates to the structural proteins of the causative agent of Pancreatic Disease in fish, nucleotide sequences encoding said proteins, vaccines comprising said proteins or nucleotide sequences and diagnostic kits comprising said proteins or nucleotide sequences. | 10-02-2008 |
20080260763 | High Throughput Proteomics - Methods to obtain expression systems and proteins in a high-throughput protocol by utilizing mixtures of cells cultured from those transformed with a desired nucleotide sequence permit rapid production of protein for use in arrays to assess activity. In one embodiment, the proteins (or peptides) in the array are assessed for their immunological activity with regard to an infectious agent. | 10-23-2008 |
20080260764 | REPLIKIN PEPTIDES AND USES THEREOF - The present invention provides isolated influenza peptides and nucleic acid sequences and methods of identifying said influenza peptides and nucleic acid sequences having a pattern of substitution of amino acids or nucleic acids in highly conserved Replikin and Replikin Scaffold sequences that is predictive of rapid replication and virulence. Methods of predicting virulence in emerging influenza strains are provided comprising identifying peptides and nucleic acid sequences having the predictive pattern of substitution. | 10-23-2008 |
20080260765 | HPV DNA Vaccines and Methods of Use Thereof - Human papillomavirus (HPV) infection is the etiological factor for cervical cancer. Provided are HPV vaccines that generate a humoral immune response to prevent new infection, as well as cell-mediated immunotherapy to eliminate established infection or HPV-related disease. HPV vaccines include nucleic acid sequences encoding HPV16 early proteins E6 and E7. Additional nucleic acid sequences in the vaccines include sequences encoding calreticulin and/or the HPV16 late protein L2. Methods using these vaccines are provided that result in therapeutic effects. | 10-23-2008 |
20080260766 | Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti-HIV-1 prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention - The present invention refers to new epitopes recognized by CD4+ T-lymphocytes. In addition, the present invention refers to the uses of such epitopes and their combinations, particularly in the treatment or prevention of disorders caused by the HIV-1 virus. | 10-23-2008 |
20080274131 | Molecular antigen arrary - The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ordered and repetitive antigen or antigenic determinant is useful in the production of vaccines for the treatment of infectious diseases, the treatment of allergies and as a pharmaccine to prevent or cure cancer and to efficiently induce self-specific immune responses, in particular antibody responses. | 11-06-2008 |
20080279877 | HPV antigens, vaccine compositions, and related methods - The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by human papilloma virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions. | 11-13-2008 |
20080279878 | Compositions of Hsp60 Peptides and Viral Antigens for Vaccination and Diagnosis - The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses. | 11-13-2008 |
20080286294 | Nodavirus-Vlp Immunization Composition - The present invention relates to an immunogenic composition for fish comprising nodavirus virus-like particles (VLPs) formed with nodavirus capsid protein assembly, for use as a vaccine. This composition is suitable for administration to fish via the intramuscular or intraperitoneal route, or by bath and/or via the oral route. The invention also relates to the use of such VPLs for the manufacturing of a vaccine for treating or preventing fish against a nodavirus infection. Fish farming baths and concentrates comprising the nodavirus VLP composition, as well as fish farming methods, are also encompassed in the present invention. | 11-20-2008 |
20080299140 | Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition - Immunogenic composition comprising at least one Herpes Simplex Virus type 1 (HSV-1) and/or type 2 (HSV-2) peptide sequence hearing at least one epitope from glycoprotein D (gD) and/or glycoprotein B (gB), a pharmaceutical carrier and/or a human compatible adjuvant, peptide sequences and uses thereof for prevention or treatment of an HSV condition. | 12-04-2008 |
20080299141 | Raccoon Poxvirus Expressing Genes of Porcine Virus - The present invention relates to a new recombinant raccoon poxvirus vector vaccine in which the vector expresses one or more antigenic proteins encoded by multiple open reading frames, preferably the ORF5, ORF6 and/or ORF3/ORF4/ORF7, of one or more porcine reproductive and respiratory syndrome virus strains alone or in combination with an open reading frame of porcine circovirus type 2 (PCV-2), preferably ORF2, at the hemagglutinin (ha) and/or thymidine kinase (tk) loci. | 12-04-2008 |
20080311143 | CONSTRUCTION OF CHIMERA PRRSV, COMPOSITIONS AND VACCINE PREPARATIONS - Chimeric replicons of North American Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) containing the 5′ sequence of an avirulent strain of PRRSV and a 3′ sequence of a virulent strain of PRRSV are provided. Further provided is a method of producing attenuated PRRSV from the chimeric replicon. Also provided are compositions containing the replicon or attenuated virus. Vaccines and a method of vaccinating pigs against PRRSV are also provided. | 12-18-2008 |
20090004215 | Chimeric G protein based rabies vaccine - A novel chimeric protein of rabies virus designed to express a chimeric G protein at a high level in transgenic plants. A gene was also designed and chemically synthesised to encode the chimeric G protein and expressed at high level in plant tissue. The gene was expressed in transgenic tobacco plants to examine its therapeutic efficacy against infection by rabies virus. The chimeric G protein was enriched in plant membranes. The BalbC mice were immunised with the plant leaf expressed G-protein. Plant derived chimeric G protein elicited higher immune response as compared to the commercial vaccine. The mice displayed protective immunity when they were challenged with live virus. Chimeric G protein expressed at high level in plant leaves was demonstrated to function as a commercially valuable subunit vaccine against rabies virus infection. | 01-01-2009 |
20090004216 | Attenuated pestiviruses - This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein E | 01-01-2009 |
20090010954 | PREVENTION AND TREATMENT OF SUB-CLINICAL PCVD - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs. | 01-08-2009 |
20090010955 | Vaccines Containing Canine Parvovirus Genetic Variants - Canine parvovirus vaccines and diagnostics and methods for their use are provided. The vaccines are effective against emerging dominant canine parvovirus variants. | 01-08-2009 |
20090017053 | Composition and Method for Preventing or Treating a Virus Infection - The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections. | 01-15-2009 |
20090022748 | Unique associated Kaposi's sarcoma virus sequences and uses thereof - This invention provides an isolated peptide encoded by a nucleic acid which is at least 30 nucleotides in length and has a sequence which uniquely defines a herpesvirus associated with Kaposis' sarcoma, which herpesvirus is present in and recoverable from the HBL-6 cell line (ATCC Accession No. CRL 11762). | 01-22-2009 |
20090022749 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 01-22-2009 |
20090022750 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 01-22-2009 |
20090022751 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 01-22-2009 |
20090022752 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 01-22-2009 |
20090028889 | Novel Polypeptide Ligands For Toll-Like Receptor 2 (TLR2) - The present invention provides novel polypeptide ligands for Toll-like Receptor 2 (TLR2). Preferrably, the novel polypeptide ligands modulate TLR2 signaling and thereby regulate the Innate Immune Response. The invention also provides vaccines comprising the novel polypeptide TLR2 ligands and an antigen. The invention further provides methods of modulating TLR2 signaling using the polypeptide ligands or vaccines of the invention. | 01-29-2009 |
20090035325 | CANINE INFLUENZA VIRUS AND RELATED COMPOSITIONS AND METHODS OF USE - The present invention provides an isolated canine influenza virus of subtype H3N8 comprising an HA having SEQ ID NO: 4 or an amino acid sequence that is greater than 99% identical to SEQ ID NO: 4, with the proviso that the amino acids at positions 94 and 233 are identical to SEQ ID NO: 4; a composition comprising attenuated or inactivated virus; isolated or purified HA, NM, NP, M1, NS1, PA, PB1, and PB2 proteins and fragments thereof and compositions comprising same or nucleic acids, optionally as part of a vector, encoding same; and a method of inducing an immune response to canine influenza virus in an animal comprising administering to the animal an aforementioned composition. | 02-05-2009 |
20090041795 | SYNTHETIC REPLIKIN PEPTIDES AGAINST PATHOGENIC INFECTION OF INVERTEBRATES IN AQUACULTURE - The present invention provides isolated or synthesized peptides of about 7 to about 50 amino acids identified in the genome of pathogens in invertebrates in aquaculture for prevention and treatment of outbreaks of these pathogens in aquaculture and methods of preventing and treating pathogenic outbreaks using the identified peptides. | 02-12-2009 |
20090047301 | Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies - The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein or peptide other than a papillomavirus L2 protein or peptide. | 02-19-2009 |
20090047302 | Chimaeric Human Papillomavirus 16 L1 Virus Like Particles and a Method for Preparing the Particles - A method for producing a chimaeric human papillomavirus (HPV) L1 polypeptide containing a heterologous peptide, and in particular, a HPV L2 peptide comprising the steps of introducing a DNA sequence coding for the heterologous peptide into a DNA sequence coding for the L1 polypeptide; introducing the DNA sequence including the sequences for the L1 polypeptide and heterologous peptide into a host cell in which the DNA sequence can be expressed; causing expression of the DNA sequence; and recovering the resulting chimaeric L1 polypeptide which includes the heterologous peptide. The invention also describes a vector for use in the method, a host cell containing the vector, and a vaccine including the chimaeric HPV L1 polypeptide produced according to the method. | 02-19-2009 |
20090053256 | Poxvirus Methods And Compositions - Methods and compositions for inducing immune responses against poxviruses are disclosed. The compositions include nucleic acids that encode modified vaccinia and variola antigens. Compositions that include recombinant vaccinia and variola polypeptides are also disclosed. | 02-26-2009 |
20090053257 | REPLIKIN PEPTIDES AND USES THEREOF - The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease. | 02-26-2009 |
20090068212 | Proteins derived from white spot syndrome virus and uses thereof - Embodiments of the present invention generally relate to proteins derived from white spot syndrome virus, nucleic acid sequences encoding them, and their use in the manufacture of a vaccine for prophylaxis and/or treatment of white spot syndrome in crustaceans. | 03-12-2009 |
20090068213 | Early detection of flaviviruses using the NS1 glycoprotein - The invention concerns a method for early detection of a flavivirus-induced infection, comprising the detection of the flavivirus non-structural glycoprotein NS1 in a biological sample during the clinical phase of the infection, by an immunological method using at least two identical or different antibodies, the first antibody consisting of polyclonal or monoclonal antibodies pre-selected for their high affinity for said NS1 protein hexameric in shape. | 03-12-2009 |
20090068214 | Methods and Compositions for Producing an Enhanced Immune Response to a Human Papillomavirus Immunogen - The present invention relates to novel methods for producing an enhanced immune response to an immunogen in a subject via the co-administration of a CD40 agonist and a GM-CSF agent. | 03-12-2009 |
20090068215 | HERPES SIMPLEX VIRUS MUTANT ICP0 PROTEIN - A mutant virus of herpes simplex virus type 1 (HSV-1) can include a mutant protein involved in replication so as to impair or inhibit replication of HSV-1. The mutant HSV-1 can have a mutation in at least one phosphorylation site of a protein involved in replication in order to inhibit phosphorylation of the site so as to prohibit or impair replication of HSV-1 and/or the clinical severity of HSV-1-mediated diseases. The mutant protein can be a mutant ICP0 that has reduced or inhibited posttranslational phosphorylation. The mutant HSV-1 and/or mutant ICP0 can be used in vaccines or other pharmaceutical preparations to treat, limit and/or prevent HSV-1 infection. The mutant HSV-1 and/or mutant ICP0 can also be used in screening and/or developing anti-HSV-1 agents. | 03-12-2009 |
20090074803 | IMMUNOGEN PLATFORM - Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines. | 03-19-2009 |
20090074804 | VERO CELL-BASED INFLUENZA VIRUS STRAINS AND VACCINES - The present invention relates to isolated influenza virus strains suitable for increased vaccine production for mammals. The influenza virus strains contain at least one modified influenza protein that results in increased production of the influenza virus from a mammalian host cell, such as a vero cell. The present invention also relates to the vaccines produced from the influenza virus strains. The present invention further relates to isolated modified influenza proteins and isolated nucleic acid molecules that encode for the modified influenza proteins. | 03-19-2009 |
20090087448 | Stable Immunoprophylactic and Therapeutic Compositions Derived From Transgenic Plant Cells and Methods for Production - The present invention generally relates to the field of immunology and provides immunoprotective compositions and methods for preparing such compositions from transgenic plant cells. The present invention also relates to the field of protein production (e.g., the recombinant production of enzymes, toxins, cell receptors, ligands, signal transducing agents, cytokines, or other proteins expressed in transgenic plant cell culture) and provides compositions comprising these proteins. | 04-02-2009 |
20090092627 | Circovirus sequences associated with piglet weight loss disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 04-09-2009 |
20090098152 | Vaccines Containing Canine Parvovirus Genetic Variants - Canine parvovirus vaccines and diagnostics and methods for their use are provided. | 04-16-2009 |
20090104216 | Peptide-Based Influenza Vaccine Formulation - Peptide-based anti-influenza formulations against influenza A and B are disclosed. The peptides are derived from influenza-based epitopes. The formulations are based on peptide mixtures which may be formulated so that variability is present at particular residues. The formulations can be used to prepare vaccines for preventing influenza in human, avian, murine or equine animals. | 04-23-2009 |
20090117140 | Human papilloma virus dominant CD4 T cell epitopes and uses thereof - Provided herein are methods of determining immunodominant T cell epitopes within a protein expressed in an individual and immunotherapy directed towards a protein in an individual using these determined epitopes. The method comprises administering autologous dendritic cells pulsed with a recombinant protein to the individual, establishing T-cell lines therefrom and incubating the T cell lines with representative peptides from the protein to measure and identify those peptides from the protein inducing the T cell response. Also provided are synthetic or recombinant peptides or immunogenic compositions thereof comprising the identified peptide(s) or peptides of similar sequence and a method of preventing or treating a pathophysiological condition. | 05-07-2009 |
20090123490 | Circovirus sequences associated with piglet weight loss disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 05-14-2009 |
20090130134 | T CD4+ Epitopes of Type I and II Latency Antigens of the Epstein-Barr Virus, Which Can Be Recognized by the majority of individuals in the caucasian populations and applications thereof - The invention relates to immunogenic peptides from EBV type I and II latency antigens, comprising at least one T CD4+ epitope which can be recognized by the majority of individuals in the Caucasian population. The invention also relates to the diagnostic and therapeutic applications of same. | 05-21-2009 |
20090136531 | HPV E6 protein T cell epitopes and uses thereof - The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population. | 05-28-2009 |
20090136532 | Vaccine for Avian Influenza and Methods of Use - The subject invention pertains to influenza vaccines and particularly avian influenza vaccines (AIV). The invention includes methods for preparing transgenic plant cells to express know HA1 polypeptides having specified homologies that are used to prepare vaccine compositions and methods for inducing protective immunity in an individual, animal, mammal or human. | 05-28-2009 |
20090148467 | HERPES SIMPLEX VIRUS COMBINED SUBUNIT VACCINES AND METHODS OF USE THEREOF - This invention provides vaccines comprising two or more recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV thereby vaccinating a subject against HSV and treating, suppressing, inhibiting, and/or reducing an incidence of an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention. | 06-11-2009 |
20090148468 | RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES AND HSV ANTIGENS IDENTIFIED VIA SAME - Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 06-11-2009 |
20090169576 | INFLUENZA COMBINATORIAL ANTIGEN VACCINE - The invention provides a combinatorial influenza vaccine composition for use in providing prophylactic protection in humans against influenza viruses or animals, and a method of producing the vaccine. | 07-02-2009 |
20090191233 | INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS - The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans. | 07-30-2009 |
20090191234 | VACCINE - This invention relates to three newly-identified, distinct groups of antigenic peptides [LB1(f) peptides] from the same region of the P5-like fimbrin protein discovered using sequence data from the fimbrin protein of many | 07-30-2009 |
20090208519 | Novel Neospora caninum Vaccine - is the causal agent of bovine neosporosis which results in high levels of abortion. The present study determined the protective efficacy of two | 08-20-2009 |
20090208520 | PRRSV GP5 BASED COMPOSITIONS AND METHODS - The disclosure includes compositions and methods for the production of an immune response against porcine reproductive and respiratory syndrome (PRRS) virus, or PRRSV. The disclosure is based in part on the use of two or more peptide domains, each with a different sequence, from the PRRSV GP5 protein ectodomain. Compositions and methods comprising polypeptides containing the two or more domains, or nucleic acids encoding them, are described. | 08-20-2009 |
20090220535 | THERAPEUTIC AND PROPHYLACTIC VACCINE FOR THE TREATMENT AND PREVENTION OF PAPILLOMAVIRUS INFECTION - Embodiments of the present invention provide compositions including a complexes of papillomavirus capsid polypeptide L2 and polypeptide including an immunotherapeutic epitope, and GST fusions thereof. Other embodiments also provide complexes comprising chimeras of papillomavirus L2 polypeptides non-covalently associated with papillomavirus L1 polypeptides, and GST fusions thereof. These compositions may be used to elicit immune responses in a patient to papillomavirus. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infection, especially papillomavirus infection and cervical cancers and warts associated therewith, made from compositions of this invention, are also disclosed. Nucleic acids and expression vectors coding for compositions are also disclosed. | 09-03-2009 |
20090246216 | NOVEL ATTENUATED POLIOVIRUS - A novel and stable attenuated poliovirus, which replicates in neuroblastoma cells, is produced by engineering an indigenous replication element (cre), into the 5′ non-translated genomic region and inactivating the native cre element located in the coding region of 2C (mono-crePV). The stably attenuated poliovirus replicates in a neuroblastoma model (Neuro-2a | 10-01-2009 |
20090258032 | METHODS AND COMPOSITIONS TARGETING VIRAL AND CELLULAR ITAM MOTIFS, AND USE OF SAME IN IDENTIFYING COMPOUNDS WITH THERAPEUTIC ACTIVITY - This invention provides methods of treating, reducing the incidence of, and inhibiting metastasis formation of carcinomas, sarcomas, Epstein-Barr virus-induced malignancies, B cell proliferative disorders, and mast cell activation disorders, comprising administering to a subject a compound that inhibits an interaction of a first protein and an immunoreceptor tyrosine-based activation motif (ITAM) of a second protein, and screening methods for identifying ITAM-inhibitory compounds and peptides. This invention also provides peptides that inhibit signaling by ITAMs. | 10-15-2009 |
20090263412 | Non-Splicing Variants of gp350/220 - Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins. | 10-22-2009 |
20090269365 | IMMUNOGENIC VACCINIA PEPTIDES AND METHODS OF USING SAME - The invention provides specific proteins encoded by the vaccinia genome that elicit an immune memory response and can be used for vaccines directed against variola (smallpox), monkeypox and other poxviruses. The invention provides antigens, polypeptides comprising antigens, polynucleotides encoding the polypeptides, vectors, and recombinant viruses containing the polynucleotides, antigen-presenting cells (APCs) presenting the polypeptides, immune cells directed against the epitopes, and pharmaceutical compositions. The invention additionally provides methods, including methods for preventing and treating infection, for killing infected cells, for inhibiting viral replication, for enhancing secretion of antiviral and/or immunomodulatory lymphokines, and for enhancing production of disease-specific antibody. | 10-29-2009 |
20090269366 | T CELL EPITOPE PEPTIDES OF 6B11 OVARIAN CANCER ANTI-IDIOTYPIC ANTIBODY - The present invention provides two T-cell epitode peptides of anti-idiotype antibody 6B11 of ovarian cancer, the sequences of which are shown in SEQ ID NO:3 or 6. The present invention also provides the use of such T-cell epitope peptides in the manufacture of vaccines against ovarian cancer and in the treatment and prevention of ovarian cancer. The T-cell epitope peptides of the present invention could specifically kill ovarian cancer cells which are OC166-9 positive, and could find a wide use in the treatment and prevention of ovarian cancer. | 10-29-2009 |
20090269367 | METHODS AND COMPOUNDS FOR MITIGATING PATHOGENIC OUTBREAKS USING REPLIKIN COUNT CYCLES - The present invention provides methods of predicting increases in pathogenic virulence, morbidity, and/or mortality or expansion in pathogen populations within regions or into new regions by identifying cycles or ratios of increasing concentrations of a family of small peptides expressed in pathogens and provides compounds comprising the small peptides for treatment and prevention of pathogenic outbreaks. | 10-29-2009 |
20090280139 | Novel Norovirus Particle for Use as an Antiviral or Vaccine - Norovirus capsid protein monomers having only the P domain, and not the hinge or S domain, can assemble spontaneously into an icosahedral form herein called the P-particle. Factors affecting the formation and stability of the P-particle, as well as providing methods for diagnosing and treating Norovirus-infected individuals and creating a vaccine for prevention of Norovirus infection are presented. | 11-12-2009 |
20090285844 | NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA - A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the htrB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation. | 11-19-2009 |
20090297547 | PHARMACEUTICAL COMPOSITION CONTAINING THE NMB0938 PROTEIN - The present invention is related to field of medicine, particularly to the development of pharmaceutical formulation containing NMB0938 protein. Formulation described in this invention is able to confer protection against different diseases caused or not by pathogenic agents. NMB0938 protein was identified as a | 12-03-2009 |
20090304729 | CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA - The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as β-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA. | 12-10-2009 |
20090304730 | INFLUENZA VACCINE - The present invention relates to influenza vaccines for human and veterinary use. In particular, the present invention provides a vaccine able to effect long term and cross-strain protection by including at least two influenza virus epitopes expressed as a chimeric polypeptide wherein at least one epitope is influenza A virus matrix protein epitope and the second epitope is a haemagglutinin peptide epitope. | 12-10-2009 |
20090311283 | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions - This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection. | 12-17-2009 |
20090311284 | Recombinant Viral Proteins And Particles - Disclosed are nucleic acids encoding fusion polypeptides containing the sequence of a Bamboo mosaic virus coat protein or a segment thereof; and an immunogenic heterologous fragment that is fused to the carrier fragment. Also disclosed are related chimeric bamboo mosaic virus particle, related expression vectors, related host cells, and related compositions. Methods of producing and using the fusion polypeptide or chimeric Bamboo mosaic virus particle are also disclosed. | 12-17-2009 |
20090317416 | INDUCTION OF IMMUNE RESPONSES TO ISOASPARTYL-MODIFIED ANTIGENS - The present invention is directed to a method of enhancing the immune response of a patient relative to the normal immune response, by administering isoaspartyl-modified proteins, peptides, or cells, to a patient. The present invention is also directed to vaccines containing the isoaspartyl-modified proteins, peptides, or cells, as well as antibodies reactive with the isoaspartyl-modified proteins, peptides, or cells. | 12-24-2009 |
20090317417 | Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof - A method of reducing the cellular immune response and/or toxicity of AAV-mediated delivery is described. The method provides for masking or ablating a RxxR motif which induces T-cells, and which is located on select AAV capsids. The method further provides for reducing or eliminating heparin binding to an AAV. Also provided are compositions containing modified AAV capsids and methods of using same. | 12-24-2009 |
20100003273 | NUCLEIC ACID VACCINES FOR PREVENTION OF FLAVIVIRUS INFECTION - The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection. | 01-07-2010 |
20100021490 | Preparation of soluble N-protein/truncated P-protein complexes or N-proteinssoluble in a virus of the paramyxoviridae family and use thereof in vaccines - The invention relates to a method for preparation of soluble N-protein/truncated P-protein complex of a virus of the family Paramyxoviridae, complexes prepared thus and the soluble N-proteins which may be isolated from said complexes. The invention further relates to vaccine compositions comprising said N-protein/truncated P-protein complexes or N-proteins from Paramyxoviridae. | 01-28-2010 |
20100021491 | PROTEIN KINASE DEFICIENT, IMMUNOLOGICALLY ACTIVE CMVpp65 MUTANT CELLULAR VACCINES - This invention relates to mutated CMVpp65, a viral structural protein which activates cell mediated immunity in humans infected with CMV. The mutations remove undesirable protein kinase activity naturally present in the protein and make it suitable for the production of both DNA and protein vaccines. Therefore, the invention provides proteins and DNAs, as well as vaccines comprising the proteins and DNAs, including cellular vaccines and vectors. Other embodiments related to the invention are methods of enhancing immune response and vaccinating against CMV, including gene therapy methods and vectors. | 01-28-2010 |
20100028375 | VLP BASED VACCINE DELIVERY SYSTEM - An isolated protein comprising a VP1 amino acid sequence wherein one or more exposed loops within said VP1 has an insertion of an amino acid sequence from a virus protein other than VP1, and encoding nucleic acid, are provided. Typically, the virus protein other than VP1 is derived from an influenza virus and in particular, avian influenza virus. The isolated protein may have an insertion of amino acid sequence from a single protein or a plurality of proteins. Also provided are expression constructs, VLPs, pharmaceutical compositions, vaccines and methods of treatment that may be useful in the prophylactic and/or therapeutic treatment of any disease of viral origin, and in particular, influenza virus. | 02-04-2010 |
20100034843 | IMMUNOGENIC COMPOSITIONS AND VACCINES FOR EBOLA - Using CTL epitopes to the Ebola GP, NP, VP24, VP30, VP35 and VP40 virion proteins, a method and composition for use in inducing an immune response which is protective against infection with Ebola virus is described. | 02-11-2010 |
20100040642 | NOVEL PEPTIDE ADJUVANT FOR INFLUENZA VACCINATION - The present disclosure generally relates to peptides having adjuvant properties, vaccines comprising the adjuvant peptides, and their use in prophylaxis or therapy for influenza. More particularly, the invention relates to adjuvant peptides that induce aggregation of influenza virus. The peptides can be included in influenza vaccines to increase the immune response to the vaccine. | 02-18-2010 |
20100047266 | CHIMERIC VIRUS-LIKE PARTICLES - Chimeric virus-like particles including gag polypeptides are described. Virus-like particles are generated with a gag polypeptide and lipid raft-associated polypeptide linked to an antigen that is not naturally associated with a lipid raft. Preferred methods of generation include expression in insect cells. | 02-25-2010 |
20100055121 | BRACHYURY POLYPEPTIDES AND METHODS FOR USE - It is disclosed herein that Brachyury is expressed in human tumors, specifically in tumors of the small intestine, stomach, kidney, bladder, uterus, ovary, and testes, as well as in lung, colon and prostate carcinomas. Immunogenic Brachyury polypeptides are disclosed herein. These polypeptides can be used in diagnostic assays for Brachyury expression, as well as for inducing an immune response to Brachyury. Polynucleotides encoding the immunogenic Brachyury polypeptides, vectors including these polypeptides, host cells transformed with these vectors, and methods of using these polypeptides, polynucleotides, vectors, and host cells are provided. Methods of diagnosing a Brachyury-expressing cancer are also provided. Exemplary cancers include lung, colon, small intestine, stomach, kidney, bladder, uterus, ovary, and testes and prostate cancers. Methods of treating cancer are also disclosed. | 03-04-2010 |
20100055122 | CHIMERIC INFECTIOUS DNA CLONES, CHIMERIC PORCINE CIRCOVIRUSES AND USES THEREOF - The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2, The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones. | 03-04-2010 |
20100062014 | H3 EQUINE INFLUENZA A VIRUS - The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof. | 03-11-2010 |
20100074914 | DNA vaccine comprising CTGF-encoding DNA construct and applications thereof - The present invention provides a DNA vaccine, which comprises a DNA construct comprising an expression vector which is expressible in a eukaryotic cell, and a nucleotide fragment which comprises a CTGF-encoding sequence and a HPV sequence selected from an E6-encoding sequence, an E7-encoding sequence, or a combination thereof. In addition, the present invention also provides a pharmaceutical composition and a method of generating said DNA vaccine. | 03-25-2010 |
20100074915 | CHIMERIC INFLUENZA VIRUS-LIKE PARTICLES - Chimeric Influenza virus-like particles including gag polypeptides are described. Virus-like particles are generated with a gag polypeptide, a neuraminidase polypeptide and optionally a hemagglutinin polypeptide. Preferred methods of generation include expression in insect cells. | 03-25-2010 |
20100080817 | HUMAN PAPILLOMAVIRUS / Ii-KEY HYBRIDS AND METHODS OF USE - The present invention is directed towards compositions comprising Ii-Key/HPV hybrid peptides. The hybrid peptides of the present invention are effective in the generation of CD4+ helper T cell immune responses directed towards the specific HPV epitopes encoded in the hybrid peptide. The inclusion of the Ii-key peptide in the hybrid causes the peptide to have greater immunogenicity as compared to control peptide. The inclusion of Ii-Key/HPV hybrid in a peptide vaccine formulation composing both HPV hybrid and HPV CTL epitope peptide (administered concurrently or sequentially) leads to a greater CTL activity against HPV CTL epitopes. The hybrid peptides of the present invention may be useful, for example, for the immunization of subjects against HPV. | 04-01-2010 |
20100111992 | CYTOMEGALOVIRUS PEPTIDES AND METHODS OF USE THEREOF - A method of modulating an immune response in a subject is disclosed. The invention is based on the discovery that an effective therapeutic strategy for ameliorating the symptoms of cytomegalovirus infection can be achieved by administering an effective amount of a CMV-derived peptide. | 05-06-2010 |
20100119535 | COMPOSITIONS AND METHODS FOR IMMUNODOMINANT ANTIGENS - Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens ( | 05-13-2010 |
20100119536 | Naturally Processed Measles Virus Peptides From Class II HLA Molecules - A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more of the peptides or antibodies to the peptide(s) are also disclosed. | 05-13-2010 |
20100119537 | TUMOR VACCINE - The invention relates to the fields of medicine, immunology, and oncology. More specifically, the invention relates to methods and compositions for inducing an immune response against a tumor in an animal subject. The invention provides that a lung cancer cell or other tumor cells, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen, and method for stimulating an immune response to a tumor with the tumor cell so genetically modified. The invention additionally provides a method of inhibiting a tumor, including a cancer such as lung cancer, by administering an allogeneic tumor cell, for example a cancer tumor cell such as a lung cancer tumor cell, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen. | 05-13-2010 |
20100136038 | NUCLEIC ACID AND AMINO ACID SEQUENCES OF INFECTIOUS SALMON ANAEMIA VIRUS AND THEIR USE AS VACCINES - The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce and immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences is herein described. | 06-03-2010 |
20100143393 | NOVEL INFLUENZA M2 VACCINES - The present invention includes novel influenza antigenic formulations and vaccines that comprise influenza M2 peptide and VLPs comprising influenza M2 protein. The invention also includes methods of making and administering the novel antigenic formulation and vaccine. The invention also include methods of inducing immunity to ameliorate and/or prevent influenza infections in a subject. | 06-10-2010 |
20100166791 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 07-01-2010 |
20100172924 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 07-08-2010 |
20100172925 | HLA-A2-RESTRICTED T-CELL EPITOPES OF THE RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN AS PEPTIDE-BASED VACCINES - Respiratory syncytial virus (RSV) fusion protein-specific T-cell epitopes as peptide-based vaccines are disclosed. The isolated peptide contains a human HLA restricted CD8+ T-cell epitope that is specific to RSV F protein. The length of the peptide is no more than 9 or 10 amino acid residues. The peptide may be employed as an immunogen to stimulate cytotoxic T cells, indirectly activate helper T cells type 1, and cause release of cytokines from T cells. | 07-08-2010 |
20100183647 | Novel human cytomegalovirus (HCMV) cytotoxic T cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor - The present invention provides CTL epitope peptides and polyepitope peptides from 14 distinct antigens of human cytomegalovirus (HCMV) that are restricted through HLA the must commonly prevalent class I alleles in different ethnic populations of the world. These epitopes provide an important platform for CTL epitope-based vaccines against HCMV. The present invention further provides vaccine compositions comprising the subject epitope and polyepitope peptides and methods for vaccination of humans and for the adoptive transfer of HCMV-specific T cells to human subjects. The present invention further provides reagents and methods for determining the HCMV status or level of HCMV-specific immunity of a subject. | 07-22-2010 |
20100183648 | VACCINE ANTIGEN CAPABLE OF INDUCING CROSS-REACTING AND NEUTRALIZING ANTIBODY AGAINTS HIGH-RISK-TYPE HUMAN PAPILLOMAVIRUS - Disclosed is a vaccine antigen capable of inducing a cross-reacting and neutralizing antibody directed against a high-risk-type human papillomavirus. Specifically disclosed are: a chimeric protein comprising an L2-epitope of a human papillomavirus (HPV) type-16 inserted in a loop region of a human papillomavirus type-16 L1 protein; and a capsid which is an aggregate of the chimeric protein. The loop region to which the L2-epitope is to be inserted is located between an amino acid residue at position-430 and an amino acid residue at position-433. The L2-epitope has an amino acid sequence represented by any one of the following formulae: YKTCKQAGTCPPDIIPKVEG (SEQ ID NO: 2) (18-32 L2-epitope); GGLGIGTGSGTGGRTGYIPL (SEQ ID NO: 3) (56-75 L2-epitope); and DPVGPLDPSIVSLVEESSFI (SEQ ID NO: 4) (96-115 L2-epitope). | 07-22-2010 |
20100183649 | METHOD OF PRODUCING VIRUS-LIKE PARTICLES OF PICORNAVIRUS USING A SMALL-UBIQUITIN-RELATED FUSION PROTEIN EXPRESSION SYSTEM - A method for producing picornaviral capsid protein complexes (e.g., picornavirus like particles) in | 07-22-2010 |
20100183650 | Antigen Delivery Vectors and Constructs - The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals. | 07-22-2010 |
20100189731 | RECOMBINANT AVIAN INFLUENZA VACCINE AND USES THEREOF - The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a subunit vaccine based on the hemagglutinin of influenza. The hemagglutinin may be expressed in plants including duckweed. The invention also encompasses recombinant vectors encoding and expressing influenza antigens, epitopes or immunogens which can be used to protect animals against influenza. It encompasses also a vaccination regimen compatible with the DIVA strategy, including a prime-boost scheme using vector and subunit vaccines. | 07-29-2010 |
20100189732 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 07-29-2010 |
20100189733 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 07-29-2010 |
20100189734 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 07-29-2010 |
20100189735 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 07-29-2010 |
20100189736 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 07-29-2010 |
20100203071 | CHIMERIC ANTIGENS - Chimeric respiratory syncytial virus (RSV) polypeptide antigens are provided. The disclosed polypeptides include in an N-terminal to C-terminal direction: a first F protein polypeptide domain; a G protein polypeptide domain; and a second F protein polypeptide domain. The disclosure also provides nucleic acids that encode, and pharmaceutical compositions that contain, the chimeric RSV polypeptides, as well as methods for their production and use. | 08-12-2010 |
20100203072 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 08-12-2010 |
20100203073 | HSV-1 EPITOPES AND METHODS FOR USING SAME - The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 08-12-2010 |
20100215679 | METHODS AND COMPOSITIONS FOR TREATING TULAREMIA - The disclosure provides an antigenic composition useful for immunization against tularemia. The disclosure provides a method for producing a vaccine for preventing tularemia in humans and animals, a new vaccine against tularemia in humans and animals, and a new approach to producing vaccines against tularemia. | 08-26-2010 |
20100215680 | REPLIKIN PEPTIDES AND ANTIBODIES THEREFOR - The present invention provides a new class of peptides related to rapid replication and their use in diagnosing, preventing and treating disease. | 08-26-2010 |
20100221275 | PROTECTION OF AN ANIMAL AGAINST PESTIVIRUS INFECTION - This invention involves compositions and methods for protecting animals from | 09-02-2010 |
20100221276 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 09-02-2010 |
20100226934 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 09-09-2010 |
20100247559 | WEST NILE VIRUS VACCINE, AND METHOD FOR PRODUCTION THEREOF - The present invention provides virus-like particles (VLP) highly secreting or producing signal peptide obtained by altering a signal sequence derived from West Nile virus (WNV), the signal peptide, a WNV VLP secretion expression vector containing a nucleic acid encoding prM protein and E protein, a WNP VLP highly secreting or producing animal cell line harboring the vector, a WNV vaccine containing WNV VLP obtained by the cell line as an active ingredient, and a WNV DNA vaccine containing the VLP secretion expression vector as an active ingredient. | 09-30-2010 |
20100255021 | TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 6 - The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections. | 10-07-2010 |
20100278852 | ANTIBODIES AGAINST AND METHODS FOR PRODUCING VACCINES FOR RESPIRATORY SYNCYTIAL VIRUS - The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection. | 11-04-2010 |
20100291128 | NOVEL COMPOSITIONS AND VACCINES AGAINST INFLUENZA A AND INFLUENZA B INFECTIONS - Novel models of interactions of the Nonstructural Protein of influenza A and influenza B viruses (NS1A and NS1B, respectively) with dsRNA are presented. On the basis of the models, novel recombinant viruses and vaccines against influenza A and influenza B viruses are provided. | 11-18-2010 |
20100291129 | Norovirus and sapovirus antigens - Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described. The immunogenic compositions of the invention may also contain antigens other than Norovirus or Sapovirus antigens, including antigens that can be used in immunization against pathogens that cause diarrheal diseases, such as antigens derived from rotavirus. | 11-18-2010 |
20100297161 | IMMUNOPROTECTIVE INFLUENZA ANTIGEN AND ITS USE IN VACCINATION - The present invention relates to an influenza antigen, comprising a fusion product of at least the extracellular part of a conserved influenza membrane protein or a functional fragment thereof and a presenting carrier, which may be a presenting (poly)peptide or a non-peptidic structure, such as glycans, peptide mimetics, synthetic polymers. The invention further relates to a vaccine against influenza, comprising at least an antigen of the invention, optionally in the presence of one or more excipients. The invention also relates to use of the antigen, a method for preparing the antigen and acceptor cells expressing the antigen. | 11-25-2010 |
20100303846 | Immunostimulatory Nucleic Acid Packaged Particles for the Treatment of Hypersensitivity - The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy. | 12-02-2010 |
20100303847 | COMPOSITIONS OF TOLL-LIKE RECEPTOR AGONISTS AND PAPILLOMAVIRUS ANTIGENS AND METHODS OF USE THEREOF - Compositions that include at least one protein that activates a Toll-like Receptor and includes at least a portion of at least one Toll-like Receptor agonist and at least a portion of at least one papillomavirus suppressor binding protein, papillomavirus transforming protein and papillomavirus capsid protein can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can further include an adjuvant and a carrier protein. | 12-02-2010 |
20100310591 | Ii-KEY HYBRID PEPTIDES THAT MODULATE THE IMMUNE RESPONSE TO INFLUENZA - The present invention provides an MHC class II antigen presentation enhancing hybrid polypeptide. The hybrid has an N-terminus comprising the mammalian Ii-key peptide LRMKLPKPPKPVSKMR (SEQ ID NO: 1) and modifications thereof which retain antigen presentation enhancing activity, a C-terminus comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule, and an intervening chemical structure covalently linking the N-terminal and C-terminal components. In a particular embodiment, the hybrid peptides of the present invention comprise influenza MHC class II epitopes identified herein as being effective in generating an immune response and provide immunity to the individual. | 12-09-2010 |
20100310592 | A TRUNCATED FORM OF THE HIV P17 PROTEIN - The invention relates to a truncated form of the HIV-1 p17 protein, designated as AT96, which consists of the residues from 1 to 96 of the full-length p17 protein, as well as the corresponding nucleic acid sequences. The truncated AT96 protein has the same immunological features as the full-length p17 protein but at the same time is devoid of the typical detrimental biological activities of the HIV-1 p17 protein. | 12-09-2010 |
20100322953 | Lipidated Tumor-Associated Antigens and Immunotherapeutic Compositions - Disclosed are polypeptides and fusion proteins. Also disclosed are related immunotherapeutic compositions and methods. | 12-23-2010 |
20110014219 | Norovirus and Sapovirus antigens - Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described. The immunogenic compositions of the invention may also contain antigens other than Norovirus or Sapovirus antigens, including antigens that can be used in immunization against pathogens that cause diarrheal diseases, such as antigens derived from rotavirus. | 01-20-2011 |
20110014220 | HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE - The present invention relates to a vaccine composition against the infection of human respiratory syncytial virus (RSV) comprising a replication-defective recombinant adenovirus carrying a nucleotide sequence encoding the F protein of RSV or fragment thereof. A method of preventing RSV infection-related diseases using the vaccine composition of the present invention is also provided. | 01-20-2011 |
20110014221 | HIV COMBINATION VACCINE AND PRIME BOOST - Provided is a novel, combination prime-boost vaccine against HIV/AIDS that induces long-lasting humoral, cell-mediated and mucosal immune responses against HIV. | 01-20-2011 |
20110020381 | INFLUENZA VACCINE FORMULATION - Peptide-based anti-influenza formulations against influenza are disclosed. The peptides are derived from influenza-based epitopes. The formulations are based on peptide mixtures which may be formulated so that variability is present at particular residues. The formulations can be used to prepare vaccines for preventing influenza, particularly avian influenza. | 01-27-2011 |
20110033489 | Circovirus sequences associated with piglet weight loss disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 02-10-2011 |
20110033490 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND/OR TREATING INFLUENZA INFECTION - The present invention provides HA polypeptides (e.g., H1 HA polypeptides) that bind to umbrella-topology glycans, and reagents and methods relating thereto. The present invention provides binding agents that bind to HA polypeptides (e.g., H1 HA polypeptides), and reagents and methods relating thereto. The present invention provides interfering agents that inhibit the binding of HA polypeptides (e.g., H1 HA polypeptides) to HA receptors, and reagents and methods relating thereto. The present invention provides compositions and methods for treating, preventing, and/or diagnosing influenza infection utilizing HA polypeptides, HA polypeptide binding agents, HA polypeptide interfering agents, and/or vaccine compositions comprising any of the foregoing. | 02-10-2011 |
20110038886 | N-Linked Glycosylation Alteration in E0 and E2 Glycoprotein of Classical Swine Fever Virus and Novel Classical Swine Fever Virus Vaccine - E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). E2 is involved in several functions including virus attachment and entry to target cells, production of antibodies, induction of protective immune response in swine, and virulence. Seven putative glycosylation sites in E2 were modified by site directed mutagenesis of a CSFV Brescia infectious clone (BICv). A panel of virus mutants was obtained and used to investigate whether the removal of putative glycosylation sites in the E2 glycoprotein would affect viral virulence/pathogenesis in swine. We observed that rescue of viable virus was completely impaired by removal of all putative glycosylation sites in E2, but restored when mutation N185A reverted to wild-type asparagine produced viable virus that was attenuated in swine. Single mutations of each of the E2 glycosylation sites showed that amino acid N116 (N1v virus) was responsible for BICv attenuation. N1v efficiently protected swine from challenge with virulent BICv at 3 and 28 days post-infection suggesting that glycosylation of E2 could be modified for development of CSF live-attenuated vaccines. Additionally, a new developed virus, contained deletions of putative glycosylation sites N1 in E2 and N1 in E0 (6b), called N1E0/2v, induce a solid protection against the challenge at 3 and 28 days post-inoculation. | 02-17-2011 |
20110052617 | AAV SCLEROPROTEIN, PRODUCTION AND USE THEREOF - The invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one mutation which brings about an increase in the infectivity of the virus. | 03-03-2011 |
20110052618 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided. | 03-03-2011 |
20110052619 | METHODS OF VACCINE ADMINISTRATION, NEW FELINE CALICIVIRUSES, AND TREATMENTS FOR IMMUNIZING ANIMALS AGAINST FELINE PARAOVIRUS AND FELINE HERPES VIRUS - The present invention relates to a vaccine for immunizing a cat against feline viruses. The present invention also relates to a nucleic acid clone that encodes the capsid protein of the isolated feline calicivirus. The present invention further relates to a live or killed vaccine comprising the isolated feline calicivirus, a subunit vaccine comprising the capsid protein of the isolated feline calicivirus, a nucleic acid vaccine comprising a nucleic acid clone of the isolated feline calicivirus, and a recombinant virus vector vaccine comprising nucleic acid encoding the capsid protein of the isolated feline calicivirus. The present invention also relates to a method for identifying a feline calicivirus useful for producing a vaccine composition and for assays for diagnosing cats infected with feline calicivirus. Also disclosed is a method of immunizing animals, especially cats, against disease, in particular against feline calicivirus (FCV). The method includes administering to a cat therapeutically effective amounts of first and second FCV vaccines. The first vaccine is administered orally or parenterally (e.g., subcutaneously, intramuscularly, and the like). The second vaccine is administered orally or oronasally N days following administration of the first vaccine, wherein N is an integer from 3 to 120, inclusive. A third vaccine administration may also be given. The present invention also describes methods and materials for treating and immunizing animals with vaccine, and in particular cats against both FPV or Feline Parvovirus, which has also been called Panleukopenia or FPL and against another disease, FHV or Feline Herpes Virus, which has also been called Feline Rhinotracheitis Virus. | 03-03-2011 |
20110064757 | NUCLEIC ACID MOLECULES AND POLYPEPTIDES FOR IMMUNE MODULATION - The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds. | 03-17-2011 |
20110064758 | INFECTIOUS CLONES OF TORQUE TENO VIRUS - The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen. | 03-17-2011 |
20110064759 | Method for the Identification of Extracellular Domains of Epstein Barr Virus (EBV) Tumor-Associated Latent Membrane Proteins and for the Selection of Antibody Reagents Reactive Therewith - Described are a method for the identification of extracellular epitopes of Epstein Barr virus (EBV) encoded membrane proteins, expressed on the cuter cell surface of EBV-transformed mammalian cells, methods for the selection and preparation of antibody reagents specific for the said epitopes, as well as peptides, including extracellular domains of Epstein Barr Virus encoded tumour cell associated membrane proteins, the use of said peptide for immunization and therapeutic vaccination to induce antibodies and T-cells reactive with said domains, the use of said antibody reagents for the production of targeting cells, tumour cell purging and as diagnostic for and medicament against EBV-mediated malignant cell growth. | 03-17-2011 |
20110070254 | MUTATIONS IN THE INFLUENZA A VIRUS NS1 GENE AND USE THEREOF - NS1 variant polypeptides, proteins or functional fragments thereof are described which have useful properties for increasing viral protein synthesis, IFN induction, and IFN resistance. The NS1 variant polypeptides, proteins or functional fragments comprise a substitution in the amino acid sequence of the wild type NS1 protein at a position corresponding to Asp-2, Val-23, Leu-98, Phe-103, Ser-103, Met-106, Met-124, Asp-125, Val-180, Val-226 or Arg-227, or combinations thereof expressed alone or in infectious virus. | 03-24-2011 |
20110081368 | Protein vaccines against poxviruses - The invention described here entails a protein vaccine against poxviruses which contains at least two purified recombinant monkeypox virus proteins or peptides. The proteins or peptides are encoded by the open reading frames of the monkeypox ortholog genes M1R, A35R, A29L B6R, and orthologs of these proteins or peptides having 90% identity. The invention also entails a vaccine protocol against poxvirus whereby a vaccine is vaccinated with a first vaccine made up of a nucleic acid vaccine of three or more poxvirus virus genes, and subsequently vaccinated with at least one other booster vaccine made up of two or more poxvirus virus proteins. | 04-07-2011 |
20110097352 | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions - This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of HBV infection. | 04-28-2011 |
20110097353 | POULTRY VIRAL MATERIALS AND METHODS RELATED THERETO - The present invention provides materials and methods for researching poultry viruses, particularly for researching infectious bronchitis viruses in poultry. Also provided are materials and methods useful for reducing the economic impact that infectious bronchitis disease has on poultry production. In one aspect of the invention, there are provided nucleic acids, amino acids and related materials and compositions useful for combating infectious bronchitis virus in poultry. | 04-28-2011 |
20110104191 | MALVA MOSAIC VIRUS AND VIRUS-LIKE PARTICLES AND USES THEREOF - The immunogenic properties of the potexvirus MaI va mosaic virus (MaMV) and virus-like particles (VLPs) comprising the coat proteins of MaMV are disclosed VLPs prepared from MaMV coat proteins, methods of preparing the VLPs, MaMV coat protein polypeptides and polynucleotides encoding the coat protein are taught. Further, immunogenic compositions comprising MaMV or a VLP comprising the MaMV coat protein alone or in combination with one or more antigens and the use of said compositions to vaccinate and/or induce an immune response in an animal are also taught. | 05-05-2011 |
20110104192 | NOROVIRUS AND SAPOVIRUS ANTIGENS - Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described. The immunogenic compositions of the invention may also contain antigens other than Norovirus or Sapovirus antigens, including antigens that can be used in immunization against pathogens that cause diarrheal diseases, such as antigens derived from rotavirus. | 05-05-2011 |
20110117118 | MOLECULES, COMPOSITIONS, METHODS AND KITS FOR APPLICATIONS ASSOCIATED WITH FLAVIVIRUSES - A method for controlling a flavivirus entry into a cell, kits for assaying the flavivirus entry into the cell, and methods of treating and preventing flaviviruses infections are disclosed, together with vaccine and pharmaceutical compositions. | 05-19-2011 |
20110123559 | SWINE INFLUENZA HEMAGGLUTININ VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 05-26-2011 |
20110123560 | Infectious Bursal Disease Virus Antigenic Isolates And Vaccines - Antigenic isolates and vaccines for Infectious Bursal Disease Virus include variants of the molecular Group 6 family of IBDV isolates, in particular the 28-1 isolate. | 05-26-2011 |
20110135677 | Circovirus sequences associated with piglet weight loss disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 06-09-2011 |
20110150911 | Methods and reagents for treating, preventing and diagnosing bunyavirus infection - Immunogenic compositions for use in treating, preventing and diagnosing infection caused by the California (CAL) serotype of the genus | 06-23-2011 |
20110150912 | Avian influenza virus live attenuated vaccine and uses thereof - Described in this application are attenuated strains of avian influenza virus containing temperature sensitive mutations in addition to a genetic tag in the PB1 gene. The attenuated viruses are useful as avian and mammalian vaccine for protective immunity against homologous and heterologous lethal challenges with influenza virus. A genetically modified avian influenza virus backbone is described which can be used as a master donor strain for the generation of live attenuated vaccines for epidemic and pandemic influenza. | 06-23-2011 |
20110150913 | TORQUE TENO VIRUS (TTV) ISOLATES AND COMPOSITIONS - The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen. | 06-23-2011 |
20110150914 | COMPOSITIONS AND METHODS FOR DENGUE VIRUS (DV) TREATMENT AND VACCINATION - The invention relates to Dengue virus (DV) peptides and compositions thereof, and methods that employ Dengue virus (DV) peptides and compositions thereof. The invention includes among other things, methods of treating Dengue virus (DV) infection or pathology, which include, for example, administering Dengue virus (DV) peptide T cell epitope, to treat a Dengue virus (DV) infection or pathology. The invention includes among other things Dengue virus (DV) vaccination and immunization methods. | 06-23-2011 |
20110159024 | SUBUNITS OF THE ADENOVIRUS FIBER PROTEIN AND USES THEREOF AS VACCINES - A nucleic acid sequence encoding a fragment of the adenovirus fiber capsid protein, a DNA construct including a replicable expression vector and at least one heterologous nucleic acid, and recombinant protein including fragment of the adenovirus fiber capsid protein. The fragment comprises the C-terminal knob and part of the shaft domain of the fiber protein of these adenoviruses. The use of recombinant proteins as an active ingredient in vaccinating compositions for conferring to an animal immunity against a pathogenic infection by an adenovirus, and methods for vaccinating a domestic bird against a pathogenic adenoviral infection. | 06-30-2011 |
20110171244 | RECOMBINANT PROTEIN CARRYING HUMAN PAPILLOMAVIRUS EPITOPES INSERTED IN AN ADENYLATE CYCLASE PROTEIN OR FRAGMENT THEREOF THERAPEUTIC USES THEREOF - The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects. | 07-14-2011 |
20110195084 | Anti-HIV Vaccine Constructed Based on Amino Acid Mutations in Attenuated Live EIAV Vaccine - Provided are antigenic polypeptides of HIV envelope glycoproteins which are constructed based on amino acid mutation of attenuated live vaccine of Equine Infectious Anemia Virus, DNA constructions and recombinant virus vectors comprising polynucleotides encoding said polypeptides, antibodies against said polypeptides as well as uses thereof in preventing and treating HIV infection. Said antigenic polypeptides and vaccines can induce high titer neutralization antibodies against HIV in organism. | 08-11-2011 |
20110200630 | LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE - The invention relates to vaccine compositions including CEV serogroup immunogens, attenuated and inactivated viruses of the CEV serogroup and chimeric Bunyaviridae. Also disclosed are methods of treating or preventing CEV serogroup infection in a mammalian host, methods of producing a subunit vaccine composition or an immunogenic composition, isolated polynucleotides comprising a nucleotide sequence encoding a CEV serogroup immunogen, methods for detecting La Crosse virus (LACV) infection in a biological sample and infectious chimeric Bunyaviridae. | 08-18-2011 |
20110206710 | Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine - Use of a recombinant lentiviral vector comprising a polynucleotide fragment encoding at least one protein of a virus of the family Flaviviridae or an immunogenic peptide of at least 8 amino acids of said protein, for preparing a pharmaceutical composition intended for the prevention and/or the treatment of a Flaviviridae infection in a sensitive species. | 08-25-2011 |
20110212117 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 09-01-2011 |
20110217327 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 09-08-2011 |
20110236407 | VACCINE FOR RUNTING-STUNTING SYNDROME - The present invention includes polypeptides, polynucleotides, antibodies, and vaccines associated with Runting Stunting Syndrome (RSS) in poultry. The present invention also includes diagnostic methods based on such polypeptides, polynucleotides, and antibodies and methods of protecting poultry, including chickens, against RSS by the administration of such polypeptides, polynucleotides, antibodies, and vaccines. | 09-29-2011 |
20110236408 | RESPIRATORY SYNCTIAL VIRUS (RSV) SEQUENCES FOR PROTEIN EXPRESSION AND VACCINES - The invention provides RSV fusion (F) protein ectodomain polypeptide sequences and nucleotide sequences encoding them, as well as cells containing the invention's polypeptide and nucleotide sequences. The invention further provides VLPs that contain the invention's polypeptides, and methods for using the VLPs for protein expression and vaccine formulation. Also provided are methods for distinguishing between subjects immunized with the invention's compositions and subjects infected with RSV. | 09-29-2011 |
20110256165 | COMPOSITIONS OF HSP60 PEPTIDES AND VIRAL ANTIGENS FOR VACCINATION AND DIAGNOSIS - The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses. | 10-20-2011 |
20110262472 | VACCINE COMPOSITIONS FOR THE TREATMENT OF DENGUE FEVER AND USES THEREOF - The invention provides compositions, vaccine compositions and pharmaceutical compositions for the treatment, amelioration and/or prevention of dengue fever. The compositions, vaccine compositions and pharmaceutical compositions of the invention comprise a virus-like particle of an RNA bacteriophage and at least one antigen, wherein said at least one antigen is a dengue antigen. When administered to an animal, preferably to a human, said compositions, vaccine compositions and pharmaceutical compositions induce efficient immune responses, in particular antibody responses, wherein typically and preferably said antibody responses are directed against dengue virus, preferably against dengue virus of any one of serotypes 1 to 4. Thus, the invention further provides methods of treating, ameliorating and/or preventing dengue virus infection by way of active immunization against domain III of the dengue virus envelope protein E, or against antigenic fragments thereof. | 10-27-2011 |
20110262473 | SYNTHETIC VACCINE COMPONENT - The present invention relates generally to the field of synthetic vaccines, components thereof and methods for producing same. More particularly, the present invention provides a component of synthetic vaccines and its use in a modular approach to vaccine production. | 10-27-2011 |
20110274710 | PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells. | 11-10-2011 |
20110280899 | Novel Immunogenic Lipopeptides Comprising T-Helper And Cytotoxic T-Lymphocyte (CTL) Epitopes - The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular CTL epitopes. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the CTL epitope. | 11-17-2011 |
20110287044 | RECOMBINANT CLASSICAL SWINE FEVER VIRUS (CSFV) COMPRISING A MODIFIED E2 PROTEIN AND METHODS FOR GENERATING SAID RECOMBINANT CSFV - The invention relates to a recombinant classical swine fever virus (CSFV). A preferred recombinant CSFV comprises a deletion of at least one amino acid in a “TAVSPTTLR” domain of the E2 protein. The invention further relates to a vaccine comprising the recombinant CSFV, a method for generating a recombinant CSFV, and use of a recombinant CSFV. | 11-24-2011 |
20110293649 | In Vivo Activation of Antigen Presenting Cells for Enhancement of Immune Responses Induced by Virus Like Particles - The invention relates to the finding that stimulation of antigen presenting cell (APC) activation using substances such as anti-CD40 antibodies or DNA oligomers rich in non-methylated C and G (CpGs) can dramatically enhance the specific T cell response obtained after vaccination with recombinant virus like particles (VLPs) coupled, fused or otherwise attached to antigens. While vaccination with recombinant VLPs fused to a cytotoxic T cell (CTL) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, VLPs injected together with anti-CD40 antibodies or CpGs induced strong CTL activity and full anti-viral protection. Thus, stimulation of APC-activation through antigen presenting cell activators such as anti-CD40 antibodies or CpGs can exhibit a potent adjuvant effect for vaccination with VLPs coupled, fused or attached otherwise to antigens. | 12-01-2011 |
20110293650 | INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING HEMAGGLUTININ - A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA of type A/California/04/09 in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein of type A/California/04/09 and plants lipids. The invention is also directed to a nucleic acid encoding influenza HA of type A/California/04/09 as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines. | 12-01-2011 |
20110293651 | HPV E6 protein T cell epitopes and uses thereof - The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population. The present invention also contemplates using E6 peptides of Human Papilloma virus as a diagnosis method to predict the probability of developing persistent cervical neoplasia in an individual. | 12-01-2011 |
20110300168 | COMPOSITIONS AND METHODS FOR INDUCING AN IMMUNE RESPONSE AGAINST INFLUENZA ANTIGENS - This disclosure provides compositions and methods for inducing an immune response against influenza antigens, for example in elderly populations, as well as a sensitive artificial antigen presenting cell (aAPC) stimulation assay that can be used for expansion and analysis of multiple antigen specific T cell populations simultaneously. | 12-08-2011 |
20110311568 | Vaccine - The present invention provides a foot and mouth disease (FMD) vaccine comprising or capable of expressing afoot and mouth disease virus (FMDV) VP1 polypeptide having a deletion of at least seven amino acids in the G-H loop such that the VP1 polypeptide lacks an RGD motif. The present invention also provides a method for preventing and/or treating FMD in a subject which comprises the step of administration of such a vaccine. | 12-22-2011 |
20110318376 | RECOMBINANT EXPRESSION OF SELF-FOLDING NEUTRALIZING EPITOPE-BEARING SUBDOMAINS OF THE RESPIRATORY SYNCYTIAL VIRUS ATTACHMENT AND FUSION PROTEINS - The present invention is directed to self-folding, soluble, stable RSV G and F polypeptides that contain a neutralizing epitope. Fusion proteins and immunogenic conjugates containing the RSV G and F polypeptides, along with recombinant transgenes and vectors, and host cells suitable for expression of such genetic constructs are also disclosed. Use of the RSV G and F polypeptides, fusion proteins, immunogenic conjugates, or a pharmaceutical composition containing the same, is contemplated for inducing a protective immune response against RSV. | 12-29-2011 |
20120003255 | FLAVIVIRUS HOST-RANGE MUTATIONS AND USES THEREOF - Methods and compositions concerning mutant flaviviruses with host-range phenotypes are provided. Nucleotide sequences that encode mutant flavivirus proteins are also provided. In certain aspects, viruses comprising these sequences display reduced replication in mammalian cells. In further aspects of the invention, flavivirus vaccine compositions and methods for vaccination against flavivirus infection are provided. | 01-05-2012 |
20120014981 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 01-19-2012 |
20120027788 | SIMIAN ADENOVIRUS NUCLEIC ACID- AND AMINO ACID-SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREOF - The present invention relates to novel adenovirus strains with an improved sero-prevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease. | 02-02-2012 |
20120027789 | ANTIGENIC PEPTIDE OF HSV-2 AND METHODS FOR USING SAME - The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV, The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 02-02-2012 |
20120027790 | IMMUNOLOGICAL HERPES SIMPLEX VIRUS ANTIGENS AND METHODS FOR USE THEREOF - The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 02-02-2012 |
20120034253 | Influenza Vaccines, Antigens, Compositions, and Methods - The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and compositions useful in inducing or enhancing an immune response agains influenza antigens. Provided are recombinant protein antigens, compositions, and methods for the production of such antigens in plants. In some embodiments, influenza antigens include hemagglutinin polypeptides, neuraminidase polypeptides, and/or combinations thereof. | 02-09-2012 |
20120039921 | POULTRY VIRAL MATERIALS AND METHODS RELATED THERETO - The present invention provides materials and methods for researching poultry viruses, particularly for researching infectious bronchitis viruses in poultry. Also provided are materials and methods useful for reducing the economic impact that infectious bronchitis disease has on poultry production. In one aspect of the invention, there are provided nucleic acids, amino acids and related materials and compositions useful for combating infectious bronchitis virus in poultry. | 02-16-2012 |
20120039922 | METHOD AND PEPTIDE FOR REGULATING CELLULAR ACTIVITY - Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject. | 02-16-2012 |
20120045467 | INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE - The present invention is directed to enhancing the immune response of a human in need of protection against IV infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof. The present invention is further directed to enhancing the immune response of a human in need of protection against IV infection by administering, in vivo, into a tissue of the human, at least one IV protein or a fragment, a variant, or derivative thereof. The IV protein can be, for example, in purified form or can be an inactivated IV, such as those present in inactivated IV vaccines. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount. | 02-23-2012 |
20120045468 | Immunogenic Compositions and Uses Thereof - Disclosed are methods of producing a purified EV71 virus antigen. Also disclosed are related immunogenic compositions and immunization methods. | 02-23-2012 |
20120045469 | VACCINE - The present invention provides an immunogenic composition comprising: an immunogenic SARS coronavirus S (spike) polypeptide, or a fragment or variant thereof; and an adjuvant comprising an oil-in-water emulsion. | 02-23-2012 |
20120058136 | NON-SPLICING VARIANTS OF gp350/220 - Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins. | 03-08-2012 |
20120070454 | DENGUE VACCINE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, NUCLEOTIDE SEQUENCE AND ANTIBODY COMPOSITION - The present invention relates to a dengue vaccine, a pharmaceutical composition comprising the same, a nucleotide sequence, and an antibody composition. The dengue vaccine of the present invention includes chimeric nonstructural protein 1, which comprises N-terminus of DV NS1 from amino-acid residues 1 to 270 and C-terminus of JEV NS1 from amino-acid residues 271 to 352 (designated DJ NS1). Therefore, the dengue vaccine without autoimmunity according to the present invention is able to avoid cross-reactions with endothelial cells and platelets, and is able to shorten the bleeding time. | 03-22-2012 |
20120070455 | INFLUENZA VACCINE - The present invention discloses isolated peptides encoding an antigen or fragments thereof from the N-terminus of hemagglutinin protein of influenza, methods for isolating such antigens and specific uses thereof. The peptide can be used as a vaccine to generate an antibody response that neutralizes influenza infectivtty against a variety of influenza strains. | 03-22-2012 |
20120076810 | VACCINIA VIRUS POLYPEPTIDES - This document provides methods and materials related to polypeptides present in a vaccinia virus (e.g., polypeptides that can be isolated from naturally processed and presented class I polypeptides originating from vaccinia virus, a member of the Orthopoxvirus family). For example, methods for generating a vaccine comprising one or more of vaccinia virus polypeptides disclosed herein for preventing or treating Orthopoxvirus infection are provided. In addition, kits related to the use of vaccinia polypeptides are provided. | 03-29-2012 |
20120076811 | IMMUNODOMINANT COMPOSITIONS AND METHODS OF USE THEREFOR - The present invention relates to immunodominant compositions, including immunodominant peptides of HA1 of influenza H5 hemagglutinin, polynucleotides encoding such peptides, and their methods of use. Such peptides are useful, for example, for the prevention, treatment and diagnosis of influenza. | 03-29-2012 |
20120082693 | USE OF PROTEINS AND PEPTIDES ENCODED BY THE GENOME OF A NOVEL SARS-ASSOCIATED CORONAVIRUS STRAIN - The invention relates to the use of proteins and peptides coded by the genome of the isolated or purified strain of severe acute respiratory syndrome (SARS)-associated coronavirus, resulting from sample reference number 031589 and, in particular, to the use of protein S and the derivative antibodies thereof as diagnostic reagents and as a vaccine. | 04-05-2012 |
20120087936 | THERAPEUTIC AND PROPHYLACTIC VACCINE FOR THE TREATMENT AND PREVENTION OF PAPILLOMAVIRUS INFECTION - Embodiments of the present invention provide compositions including a complexes of papillomavirus capsid polypeptide L2 and polypeptide including an immunotherapeutic epitope, and GST fusions thereof. Other embodiments also provide complexes comprising chimeras of papillomavirus L2 polypeptides non-covalently associated with papillomavirus L1 polypeptides, and GST fusions thereof. These compositions may be used to elicit immune responses in a patient to papillomavirus. Therapeutic and prophylactic vaccines for the prevention and treatment of viral infection, especially papillomavirus infection and cervical cancers and warts associated therewith, made from compositions of this invention, are also disclosed. Nucleic acids and expression vectors coding for compositions are also disclosed. | 04-12-2012 |
20120087937 | NOVEL COMPOSITIONS - This disclosure provides novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease. The constructs are chimeric proteins comprising L1 proteins with an HPV L2 peptide inserted in to the L1 protein. Such chimeric proteins may be formulated into immunogenic e.g., vaccine compositions, and optionally formulated with HPV L1 VLP based vaccines. | 04-12-2012 |
20120093847 | RECOMBINANT RSV VACCINES - This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection. | 04-19-2012 |
20120093848 | IMMUNOGENIC COMPOSITION COMPRISING PEPTIDES DERIVED FROM CYTOMEGALOVIRUS AND THE USE THEREOF - The present invention provides (poly)peptides, which are recognized by human cytomegalovirus (CMV)-specific immune cells. The present invention further provides a combination of multiple CMV (poly)peptides, comprising at least two different groups of (poly)peptides according to the invention as well as conjugates, comprising said (poly)peptides and/or immune adjuvants thereof. Furthermore, this invention provides mixtures, comprising said (poly)peptides and/or immune cells thereof, which are used to generate CMV-specific immune effector cells with high sensitivity and specificity. In addition, the present invention provides a preparation method of CMV-specific immune effector cells, by using said (poly)peptides, adjuvants, immune cells and/or mixtures thereof to generate anti-CMV immune response. | 04-19-2012 |
20120100168 | CYCLOVIRUS AND METHODS OF USE - Provided herein are sequences of the genomes and encoded proteins of a novel virus, termed cyclovirus, and variants thereof. Also provided are methods of detecting cyclovirus and diagnosing cyclovirus infection, methods of treating or preventing cyclovirus infection, and methods for identifying anti-cyclovirus compounds. Further provided are vaccines and methods of preventing cyclovirus-related diseases in animals, such as pigs. | 04-26-2012 |
20120100169 | Vaccine for Cervical Cancer - The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer. | 04-26-2012 |
20120114683 | Nucleic Acid Encoding TGEV and PRRSV Sequences for Improved Expression of PRRSV Sequences - The present invention relates to nucleic acids comprising:
| 05-10-2012 |
20120121628 | LIPIDATED POLYEPITOPE VACCINES - This invention relates to, inter alia, an isolated lipidated polypeptide including a lipid moiety at the N-terminus and a plurality of epitopes, and methods of making and using the polypeptide. | 05-17-2012 |
20120121629 | NEW HUMAN ROTAVIRUS VACCINE STRAINS AND DIAGNOSTICS - A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine. | 05-17-2012 |
20120121630 | RECOMBINANT ECTODOMAIN EXPRESSION OF HERPES SIMPLEX VIRUS GLYCOPROTEINS IN YEAST - The present invention provides Herpes Simplex Virus (HSV) gD, gC, gB and/or gE recombinant glycoproteins having a particular pre-selected N-linked glycosylation pattern as the predominant N-glycoform. The present invention also provides methods of producing these recombinant glycoproteins in yeast, preferably | 05-17-2012 |
20120135021 | CELL PENETRATING PEPTIDES AND ITS USE FUSED TO BIOMOLECULES WITH THERAPEUTIC ACTION - The present invention relates to use of a new cell penetrating peptides (CPP) and in particular to the region 32-51 of protein | 05-31-2012 |
20120135022 | ASSEMBLY ACTIVATING PROTEIN (AAP) AND ITS USE FOR THE MANUFACTURE OF PARVOVIRUS PARTICLES ESSENTIALLY CONSISTING OF VP3 - The present invention relates to nucleic acids encoding the novel parvoviral protein “assembly activating protein” (AAP), the encoded polypeptides, methods of producing the polypeptides, antibodies specific for AAP, the use of the nucleic acids for the preparation of the polypeptides, the use of the nucleic acids or the polypeptides for the preparation of the parvoviral particle and methods of producing parvoviral particles essentially consisting of VP3 by providing in addition to the coding sequence of the parvoviral structural protein VP3 a sequence fragment Z/a nucleic acid encoding AAP in the cell and expressing VP3 and fragment Z under control of a rep-independent promoter. Furthermore, the present invention relates to parvoviral particles essentially consisting of VP3 and/or obtainable by the above method as well as expression cassettes comprising (i) a heterologous promoter and (ii) VP3 coding sequence and/or fragment Z. The present invention further relates to a medicament, particularly a vaccine, comprising the parvoviral particles or expression cassettes and their use. | 05-31-2012 |
20120135023 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 05-31-2012 |
20120141518 | Human Parvovirus: Bocavirus - Provided herein are sequences of the genomes and encoded proteins of a new human parvovirus, Bocavirus-2, and variants thereof. Also provided are methods of detecting the Bocavirus-2 and diagnosing Bocavirus-2 infection, methods of treating or preventing Bocavirus-2 infection, and methods for identifying anti-Bocavirus-2 compounds. | 06-07-2012 |
20120141519 | REAGENTS AND METHODS FOR DETECTING INFLUENZA VIRUS PROTEINS - Two universally conserved sequences from influenza type A neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the N-terminus of the type A neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed. Quantitative analyses of NA using slot blot suggest that the antibodies can be used for NA antigen quantitation in vaccines. These represent the first time the antibody-based immunoassay can be used for NA quantitative determination. | 06-07-2012 |
20120141520 | RECOMBINANT SUBUNIT WEST NILE VIRUS VACCINE FOR PROTECTION OF HUMAN SUBJECTS - A West Nile virus vaccine for human use is described that preferably contains a recombinantly produced form of truncated West Nile virus envelope glycoprotein and aluminum adjuvant. The vaccine is acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. The vaccine is safe and effective for use in all healthy and at-risk populations. A pharmaceutically acceptable vehicle may also be included in the vaccine. | 06-07-2012 |
20120156235 | Antibodies Against And Methods For Producing Vaccines For Respiratory Syncytial Virus - The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection. | 06-21-2012 |
20120177675 | Chimaeric Protein - The present invention provides a chimaeric coronavirus S protein which is based on an S protein from a coronavirus strain with restricted tissue tropism, but which comprises at least part of the S2 subunit from a coronavirus strain with extended tissue tropism, such that a virus comprising the chimaeric S protein has extended tissue tropism. The present invention also provides a virus comprising such a chimaeric S protein. | 07-12-2012 |
20120177676 | ALPHABODIES FOR HIV ENTRY INHIBITION - The present invention relates to HIV-1 gp41-binding single-chain 3-stranded alpha-helical coiled coil molecules, denoted “Alphabodies”, nucleic acids encoding said Alphabodies, host cells comprising said nucleic acids, as well as pharmaceutical compositions comprising said Alphabodies, and methods for the treatment, prevention and diagnosis of HIV infection using said Alphabodies. | 07-12-2012 |
20120189647 | POLYPEPTIDE SEQUENCE INVOLVED IN THE MODULATION OF THE IMMUNOSUPPRESIVE EFFECT OF VIRAL PROTEINS - Mutated viral ENV proteins having mutations in the immunosuppressive domain (ISU) of the transmembrane subunit (TM) have decreased immunosuppressive activity with respect to the wild-type ENV protein. Pharmaceutical compositions that include the protein and nucleic acids coding for the protein are also disclosed. | 07-26-2012 |
20120213810 | NOVEL EUROPEAN PRRSV STRAIN - The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines. | 08-23-2012 |
20120219576 | LASSA VIRUS-LIKE PARTICLES AND METHODS OF PRODUCTION THEREOF - The instant invention is directed to novel Lassa virus-like particle (VLP) compositions and methods of production thereof. The inventive VLPs comprise, for example, the Lassa virus (LASV) Z matrix protein, glycoproteins (GPs)-I and -2, and nucleoprotein (NP). A novel method for producing these VLPs comprises constructing multicistronic plasmids for the expression of VLP protein components from a single vector. One example is a tricistronic vector containing DNA sequences encoding the LASV Z, GPC and NP proteins. The VLPs provided by the present invention can be used for research, therapeutic and diagnostic purposes. | 08-30-2012 |
20120225090 | METHODS FOR ENHANCING ANTIGEN-SPECIFIC IMMUNE RESPONSES - Methods for delivering naked DNA vaccines to enhance immune responses, by improving transfection efficiency without safety concerns associated with live viral vectors, are described. A method may comprise administering to a mammalian subject an effective amount of a papillomavirus pseudovirion, wherein the papillomavirus pseudovirion comprises at least one papillomavirus capsid protein encapsidating a naked DNA vaccine, wherein the naked DNA vaccine comprises a first nucleic acid encoding at least one antigen, thereby enhancing the antigen specific immune response relative to administration of the naked DNA vaccine. | 09-06-2012 |
20120231027 | NOVEL H5 PROTEINS, NUCLEIC ACID MOLECULES AND VECTORS ENCODING FOR THOSE, AND THEIR MEDICINAL USE - The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals. | 09-13-2012 |
20120237535 | Therapeutic Compositions For The Treatment of HPV-Induced Diseases - The invention relates to immunogenic conjugates comprising an immunogenic region of human papilloma virus E7 protein and the fibronectin EDA region, as well to compositions comprising said conjugates and to dendritic cells obtained by stimulation with said conjugates and compositions. Moreover, the invention relates to methods for the treatment of diseases caused by the human papilloma virus (HPV) using said conjugates, compositions and dendritic cells. | 09-20-2012 |
20120251564 | REOVIRUS COMPOSITIONS AND METHODS OF USE - The present invention relates to novel strains of avian reovirus isolated from severe cases of Runting Stunting Syndrome in young broiler chickens in southeast United States. The invention is directed to avian reoviruses that impair digestion in poultry, diagnostic assays using nucleotide- or amino acid-specific components of such viruses, and to vaccines that protect chickens from disease caused by such viruses. Nucleotide sequences for the S1 gene, encoding the sigma C minor outer capsid protein, were amplified, and the nucleotide and predicted amino acid sequences were compared with sequences from other recently isolated reovirus field isolates and vaccine strains. Antigenic and molecular characterization of the newly isolated reoviruses revealed a lack of homogeneity with current U.S. isolates, with less than 60% percent amino acid similarity across the sigma C protein. Sequence comparisons with previously reported malabsorption isolates from Europe and Asia revealed a higher amino acid similarity, approaching 80%. | 10-04-2012 |
20120258126 | Molecular Vaccines for Infectious Disease - The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals. | 10-11-2012 |
20120258127 | VACCINE PEPTIDES - There is provided a polypeptide having an amino acid sequence selected from SEQ ID NOs:1, 2 and 3 or a functional fragment thereof, or comprising an amino acid sequence at least 65% identical to any one of SEQ ID NOs:1, 2 or 3. There is also provided a method of rapidly vaccinating an animal against infection by a pestivirus comprising administering to the animal an effective amount of a polypeptide comprising an E2 epitope polypeptide and/or an NS3 epitope polypeptide; the E2 epitope polypeptide may be SEQ ID NO:1 and the NS3 epitope polypeptide may be SEQ ID NO:2 or 3, or functional fragments thereof. | 10-11-2012 |
20120263743 | INFLUENZA HEMAGGLUTININ COMPOSITIONS AND USES THEREOF - The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions, vaccine compositions and pharmaceutical compositions for the treatment, amelioration and/or prevention of influenza. The compositions, vaccine compositions and pharmaceutical compositions of the invention comprise a virus-like particle of an RNA bacteriophage and at least one antigen, wherein said at least one antigen is an ectodomain of an influenza virus hemagglutinin protein or a fragment of said ectodomain of an influenza virus hemagglutinin protein. When administered to an animal, preferably to a human, said compositions, vaccine compositions and pharmaceutical compositions efficiently induce immune responses, in particular antibody responses, wherein typically and preferably said antibody responses are directed against influenza virus. Thus, the invention further provides methods of treating, ameliorating and/or preventing influenza virus infection. | 10-18-2012 |
20120263744 | Compositions And Methods Involving Respiratory Syncytial Virus Subgroup B Strain 9320 - The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g., attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides. Related methods are also described. | 10-18-2012 |
20120282287 | Novel Flavivirus Antigens - The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided. | 11-08-2012 |
20120288515 | SYNTHETIC LONG PEPTIDE (SLP)-BASED VACCINES - Synthetic long peptides and an adjuvant are formulated together and administered to a subject in order to raise an immune response. In certain embodiments, the adjuvant is GLA. | 11-15-2012 |
20120294878 | TLR-2 AGONISTS AND METHODS OF USE THEREOF - Two new TLR2 agonists, VP1 and VP3, which are structural proteins of FMDV. Residues of VP3 responsible for TLR2 activation are identified. In vivo experiments showed that VP3-4xM2e is active as a vaccine adjuvant. | 11-22-2012 |
20120294879 | CONSENSUS SEQUENCE FOR INFLUENZA A VIRUS - Pandemic A(H1N1) continues its global spread, and vaccine production is a serious problem. Protection by current vaccines is limited by the mutational differences that rapidly accumulate in the circulating strains, especially in the virus surface proteins. New vaccine strategies are focusing at conserved regions of the viral internal proteins to produce T cell epitope-based vaccines. T cell responses have been shown to reduce morbidity and promote recovery in mouse models of influenza challenge. We previously reported 54 highly conserved sequences of NP, M1 and the polymerases of all human H1N1, H3N2, H1N2, and H5N1, and avian subtypes over the past 30 years. Sixty-three T cell epitopes elicited responses in HLA transgenic mice (A2, A24, B7, DR2, DR3 and DR4). These epitopes were compared to the 2007-2009 human H1N1 sequences to identify conserved and variant residues. Seventeen T cell epitopes of PB1, PB2, and M1 were selected as vaccine targets by analysis of sequence conservation and variability, functional avidity, non-identity to human peptides, clustered localization, and promiscuity to multiple HLA alleles. The vaccines composed of these epitopes, being highly conserved and temporally stable, would be useful for any avian or human influenza A virus. | 11-22-2012 |
20120301493 | APPLICATIONS OF THE PROTEIN MUNS AND THE DERIVATES THEREOF - The invention is based on the identification of the minimum region of the avian | 11-29-2012 |
20120308592 | Immunogenic HPV L2-Containing VLPs and Related Compositions, Constructs, and Therapeutic Methods - The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection. | 12-06-2012 |
20120321653 | NOVEL CHIMERIC POLYNUCLEOTIDES AND POLYPEPTIDES ENABLING THE SECRETION OF A POLYPEPTIDE OF INTEREST IN COMBINATION WITH EXOSOMES AND USES THEREOF - The present invention provides a chimeric polypeptide comprising a plurality of polypeptide domains that are capable of being secreted in combination with membrane vesicles and in particular exosomes. | 12-20-2012 |
20120321654 | INFECTIOUS CLONES OF TORQUE TENO VIRUS - The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen. | 12-20-2012 |
20130011425 | RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES AND HSV ANTIGENS IDENTIFIED VIA SAME - Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 01-10-2013 |
20130011426 | Recombinant Vaccines and Use Thereof - The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule. | 01-10-2013 |
20130011427 | FLAVIVIRUS SPECIES-SPECIFIC PEPTIDE TAGS FOR VACCINE AND DIAGNOSTIC USE - Flaviviruses represent an increasing global public health issue, with no prophylactic and therapeutic formulations currently available for many of them. The combination of factors such as evolutionary change, global warming and wide range of animal hosts suggest the possible occurrence of | 01-10-2013 |
20130022631 | VACCINE FOR CHIKUNGUNYA VIRUS INFECTION - The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikun-gunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikun-gunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus. | 01-24-2013 |
20130022632 | RECOMBINANT FELINE LEUKEMIA VIRUS VACCINE CONTAINING OPTIMIZED FELINE LEUKEMIA VIRUS ENVELOPE GENE - The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions. | 01-24-2013 |
20130028924 | CONSTRUCTS FOR ENHANCING IMMUNE RESPONSES - Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided. | 01-31-2013 |
20130028925 | HERPES SIMPLEX VIRUS COMBINED SUBUNIT VACCINES AND METHODS OF USE THEREOF - This invention provides immunogenic compositions comprising two or three recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV, inducing an anti-HSV immune response, and treating, suppressing, inhibiting, and/or reducing an incidence of an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention. | 01-31-2013 |
20130034576 | NOVEL ADENOVIRUS ISOLATED FROM TITI MONKEYS - Provided is a Titi Monkey Adenovirus (TMAdV) that can infect both human and non-human primates. Further provided are nucleic acid sequences, proteins, expression vectors and host cells, anti-TMAdV antibodies, vaccines, compositions, methods of detecting TMAdV, methods for assaying for anti-TMAdV compounds, and methods for treating or preventing a TMAdV infection. | 02-07-2013 |
20130064843 | Identification of conserved peptide blocks in homologous polypeptides - Methods for identifying at least one conserved peptide block in three or more homologous polypeptides are provided and compositions comprising conserved peptides are provided. More particularly, methods for selecting conserved peptides in variable viral polypeptides for use in immunogenic compositions are provided. | 03-14-2013 |
20130064844 | NON-SPLICING VARIANTS OF GP350/220 - Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins. | 03-14-2013 |
20130071418 | Physicochemical (PCP) Based Consensus Sequences and Uses Thereof - Provided herein is a computational method for designing a PCP-consensus protein for a family of related proteins. The method uses a consensus alignment of a protein domain common to all the related proteins, which may or may not be substantially biased, from which an average value of p, e.g., 5, physicochemical properties are calculated for each amino acid in the alignment. The PCP-consensus protein has a sequence derived from an alignment of protein domains from a family of related proteins, said sequence containing one or more motifs common to all of the proteins. Also provided are the PCP-consensus proteins, kits comprising the same, datasets of aligned consensus sequences used to derive the PCP-consensus proteins and methods of eliciting an immune response, diagnosing or treating an infectious disease using the same. | 03-21-2013 |
20130071419 | UNIVERSAL DENGUE VIRUS SEQUENCES AND METHODS OF USE - Disclosed herein are computationally optimized broadly reactive dengue virus E polypeptide sequences for DENV-1, DENV-2, DENV-3 and DENV-4. Also disclosed are dengue virus E protein fragments (such as the E protein ectodomain and DIII domain) fused to the molecular adjuvant P28. The disclosed nucleic acid and polypeptide sequences can be used as vaccines for immunization against dengue virus infection. In some cases, the vaccine includes a virus-like particle containing the universal dengue virus E protein, or fragment thereof, or the vaccine is a DNA molecule encoding the VLP. | 03-21-2013 |
20130089567 | DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS - The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3′ untranslated region (3′-UTR) comprising a Δ30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR that removes sequence in the 5′ direction as far as the 5′ boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3′-UTR of a dengue virus of a first serotype with the 3′-UTR of a dengue virus of a second serotype, optionally containing the Δ30 mutation and nucleotides additional to the Δ30 mutation deleted from the 3′-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus. | 04-11-2013 |
20130095130 | Methods and Compositions for Providing Protective Immunity in the Elderly - Compositions that include a flagellin/antigen protein comprising at least a portion of at least one flagellin and at least a portion of at least one antigen and methods of administering these compositions to humans at least 49 years old. The compositions stimulate immune response to the antigen, in particular, a protective immune response to the antigen, in the human, such as an elderly human. | 04-18-2013 |
20130115234 | Ectodomains of Influenza Matrix 2 Protein, Expression System, and Uses Thereof - The present invention provides a polynucleotide, polypeptide, recombinant modified vaccinia virus Ankara (rMVA) and related vaccine compositions and methods useful in the prevention and treatment of an influenza viral infection. Provided is an isolated polynucleotide encoding multiple copies of M2 influenza ectodomain peptides or rMVA comprising the polynucleotide. Also provided are methods for inducing an immune response to a subject against an influenza virus or for treating a disease or symptom caused by or resulting from infection with an influenza virus. | 05-09-2013 |
20130115235 | SWINE INFLUENZA HEMAGGLUTININ VARIANTS - The technology relates in part to modified influenza viruses useful for vaccine development. Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 05-09-2013 |
20130115236 | PROPHYLAXIS AND TREATMENT OF PRDC - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs. | 05-09-2013 |
20130122032 | RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 05-16-2013 |
20130129761 | INFLUENZA VIRUS VACCINE AND USES THEREOF - Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use. | 05-23-2013 |
20130129762 | MARKER VACCINE FOR CLASSICAL SWINE FEVER - The invention relates to a marker vaccine for prophylactic treatment of classical swine fever comprising modified live attenuated classical swine fever virus. The viral amino acid sequence of the TAV-epitope of the E2 protein comprises a different sequence from that of a wild-type classical swine fever virus. The invention relates to pharmaceutical compositions of the marker vaccine. The invention also relates to a method of manufacturing marker vaccines for prevention of classical swine fever using selective antibody pressure. | 05-23-2013 |
20130136759 | ANTI-RSV IMMUNOGENS AND METHODS OF IMMUNIZATION - Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof. | 05-30-2013 |
20130149323 | MUTATED LENTIVIRAL ENV PROTEINS AND THEIR USE AS DRUGS - A pharmaceutical composition includes, as active substance a mutated lentiviral ENV protein, substantially devoid of immunosuppressive properties or a variant of the mutated lentiviral ENV protein or a fragment of the above proteins, in association with a pharmaceutically acceptable carrier. | 06-13-2013 |
20130156800 | IDENTIFICATION OF PROTECTIVE ANTIGENIC DETERMINANTS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF - The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV. | 06-20-2013 |
20130164315 | Vaccines - Screening Method - The present invention provides a screening method for identifying a peptide capable of inducing a T cell response comprising:
| 06-27-2013 |
20130171181 | DPS FUSION PROTEINS FOR USE IN VACCINES AND DIAGNOSTICS - Novel nanoparticle fusion proteins comprising proteins or peptides fused to Dps (DNA-binding protein from starved cells) proteins are provided which bring forth distinct advantages for development of new and improved vaccines, diagnostic tests, and other biomedical products. | 07-04-2013 |
20130177582 | PARAPOXVIRUS EXPRESSING THE VP60 MAJOR CAPSID PROTEIN OF THE RABBIT HAEMORRHAGIC DISEASE VIRUS - The invention describes a therapeutic agent capable of treating and/or preventing rabbit haemorrhagic disease virus infection in rabbits, namely a recombinant parapoxvirus, characterized in that the VP60 major capsid protein from the rabbit haemorrhagic disease virus (RHDV) is expressed from a foreign nucleic acid. | 07-11-2013 |
20130183329 | Interferon-Inducing Porcine Reproductive and Respiratory Syndrome Virus Isolate - Provided are polynucleotides and proteins encoded by them which are useful for stimulating an immune response against Porcine reproductive and respiratory syndrome virus (PRRSV) in swine. The compositions can contain a newly discovered PRRSV strain or recombinant versions of it or polynucleotides isolated or derived from it, which can be provided as pharmaceutical preparations. | 07-18-2013 |
20130189293 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided. | 07-25-2013 |
20130189294 | RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES AND HSV ANTIGENS IDENTIFIED VIA SAME - Described is a method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 07-25-2013 |
20130195904 | HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) HIGHLY CONSERVED AND LOW VARIANT SEQUENCES AS TARGETS FOR VACCINE AND DIAGNOSTIC APPLICATIONS - We identified regions of the HIV-1 proteome with high conservation, and low variant incidence. Such highly conserved sequences have direct relevance to the development of new-generation vaccines and diagnostic applications. The immune relevance of these sequences was assessed by their correlation to previously reported human T-cell epitopes and to recently identified human HIV-1 T-cell epitopes (identified using HLA transgenic mice). We identified (a) sequences specific to HIV-1 with no shared identity to other viruses and organisms, and (b) sequences that are specific to primate lentivirus group, with multiclade HIV-1 conservation. | 08-01-2013 |
20130195905 | Composition for Preventing or Treating Cervical Cancer Having Human Papillomavirus Plasmodium and Immunity Enhancer - A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18. | 08-01-2013 |
20130195906 | H3 EQUINE INFLUENZA A VIRUS - The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof. | 08-01-2013 |
20130202634 | Dengue Virus (DV) Polypeptide Sequences, T Cell Epitopes and Methods and Uses Thereof - Dengue virus (DV) peptides, including T cell epitopes, structural and non-structural (NS) polypeptide sequences, subsequences and modifications thereof, nucleotide sequences encoding such peptides, and compositions including such peptides and encoding nucleotide sequences, and cells expressing such peptides, are provided. Such DV peptides, nucleotide sequences and compositions, can be used to elicit, stimulate, induce, promote, increase, enhance or activate an anti-DV CD8 | 08-08-2013 |
20130209499 | VACCINES FOR USE IN THE PROPHYLAXIS AND TREATMENT OF INFLUENZA VIRUS DISEASE - Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their use to generate an immune response against multiple influenza subtypes in a subject. | 08-15-2013 |
20130216566 | Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using - SARS (severe acute respiratory syndrome virus, a coronavirus) immunogens, antigens, or epitopes, nucleic acid molecules encoding such immunogens, antigens, or epitopes; vectors containing such nucleic acid molecules, e.g., viral vectors such as baculovirus vectors, DNA vectors, such as DNA plasmid vectors, e.g., DNA plasmids that express a nucleic acid molecule in a mammalian cell, uses for such immunogens, antigens or epitopes and vectors, e.g., as an active component immunogenic, immunological or vaccine compositions, or to generate antibodies, such as monoclonal antibodies, and methods for making, and using such immunogens, antigens or epitopes, vectors, antibodies, including in methods for eliciting an immunological or immunogenic or vaccine response, as well as in assays or diagnostic kits or methods, are discussed, as well as a seamless fusion of sequences in a plasmid or vector, e.g., a sequence encoding a leader sequence and a sequence encoding a protein, epitope or immunogen or antigen. | 08-22-2013 |
20130216567 | AVIAN GROUP D ROTAVIRUS - The invention relates to a newly identified avian rotavirus D VP6 nucleotide sequence and uses thereof. | 08-22-2013 |
20130224235 | POTATO VIRUS A COAT PROTEIN-BASED VACCINES FOR MELANOMA - A vaccine for treating melanoma, comprising at least one melanoma antigen and a viral-like particle comprising potato virus A coat protein. Use of vaccine for treating melanoma, including protein and DNA vaccines, based on potato virus A coat protein. | 08-29-2013 |
20130224236 | HSV-1 EPITOPES AND METHODS FOR USING SAME - The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 08-29-2013 |
20130230548 | TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 52 - Provided is a truncated L1 protein of Human Papillomavirus (HPV) Type 52 which, compared to a wild type HPV52 L1 protein, is truncated by 27-42 amino acids at the N-terminal. Also provided are a coding sequence of the truncated HPV52 L1 protein, a virus-like particle (VLP) comprising the protein, and a method of preparing the protein and the VLP using an | 09-05-2013 |
20130230549 | FOOT AND MOUTH DISEASE VIRUS WITH INCREASED STABILITY AND ITS USE AS VACCINE - The present invention provides a foot and mouth disease (FMD) virus having improved stability compared to the field isolate of the same subtype, wherein the virus comprises one or more amino acid mutations along a line of symmetry of the capsid structure. The present invention also relates to a vaccine comprising such an FMD virus and its use to prevent foot and mouth disease. | 09-05-2013 |
20130236486 | IMMUNOGENIC VACCINE - A glycolipopeptide comprising a carbohydrate component, a lipid component, and a MUC1 peptide component that induces both a humoral and a cellular immune response for use as a therapeutic or prophylactic vaccine. | 09-12-2013 |
20130236487 | DESIGNER PEPTIDE-BASED PCV2 VACCINE - Porcine circovirus (PCV2) vaccine compositions comprising a peptide antigen derived from a PCV2 capsid protein are described. In various embodiments, the peptide antigen contains amino acids of the capsid protein from about amino acid 47 to about amino acid 202. In some embodiments, the peptide antigen is optionally linked to an artificial T helper epitope and/or mixed with T helper epitopes derived from the ORF1 and ORF3 proteins of PCV2. Methods of using PCV2 vaccine compositions are also described. In various embodiments, a vaccine composition is used in animals for the prevention of PCV2 infection. In other embodiments, a PCV2 vaccine composition is used as an antigen for diagnosing PCV2 infection. | 09-12-2013 |
20130243803 | THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR INFECTIOUS SALMON ANEMIA VIRUS - The present invention provides therapies, vaccines, and predictive methods for infectious salmon anemia virus and provides compounds for diagnosing, preventing, and treating outbreaks of infectious salmon anemia virus including compounds for diagnosing, preventing, and treating infectious salmon anemia across different strains of virus. | 09-19-2013 |
20130243804 | Peptide Sequences and Compositions - Provided is a polypeptide having no more than 100 amino acids, which polypeptide comprises one or more sequences having at least 60% homology with any of SEQ ID 1-6, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-6 that has the same length as the epitope: | 09-19-2013 |
20130251737 | Modified Mareks Disease Virus, and Vaccines Made Therefrom - The present invention provides an effective vaccine for Marek's disease, which may be prepared using a recombinant Marek's Disease Virus (MDV), strain CVI988, having been transformed with a foreign DNA construct that includes a long terminal repeat sequence of a reticuloendotheliosis virus. This safe viral agent elicits a highly protective immune response in a chicken against virulent MDV challenge without causing a significant degree of pathogenicity. Suitable formulations of the vaccine for use in chickens include an effective immunization dosage of this novel viral agent, along with a pharmaceutically acceptable carrier or diluent. | 09-26-2013 |
20130259886 | BROADLY PROTECTIVE INFLUENZA T-CELL VACCINE AGAINST DIVERSE INFLUENZA A VIRUSES - There is provided a T cell-based universal influenza vaccine including internal genes capable of preparing against infection by broad hetero-subtypic influenza viruses, and thereby preparing for unpredictable epidemic influenza. The present invention selected internal genes of the consensus sequence obtained from bird, pig, and human influenza isolates in order to develop the T cell-based universal flu vaccine. The T cell-based universal flu vaccine according to the present invention is characterized by including at least one CTL epitope, by containing a plurality of internal genes and using the entire sequence of the internal gene itself. The T cell-based universal flu vaccine can achieve broad defense in infection with hetero-subtypic influenza viruses. | 10-03-2013 |
20130266600 | Functional Mutations In Respiratory Syncytial Virus - The present invention provides recombinant respiratory syncytial viruses that have an attenuated phenotype and that comprise one or more mutations in the viral P, M2-1 and/or M2-2 proteins, as well as live attenuated vaccines comprising such viruses and nucleic acids encoding such viruses. Recombinant RSV P, M2-1 and M2-2 proteins are described. Methods of producing attenuated recombinant RSV, and methods of quantitating neutralizing antibodies that utilize recombinant viruses of family Paramyxoviridae, are also provided. | 10-10-2013 |
20130266601 | Mycoplasma Hyopneumoniae Vaccine - This invention provides an immunogenic composition including a soluble portion of a | 10-10-2013 |
20130266602 | PCV/Mycoplasma Hyopneumoniae Combination Vaccine - This invention provides a multivalent immunogenic composition including a soluble portion of a | 10-10-2013 |
20130266603 | PCV/Mycoplasma Hyopneumoniae/PRRS Combination Vaccine - This invention provides a trivalent immunogenic composition including a soluble portion of a | 10-10-2013 |
20130273088 | EPITOPES OF HERPES SIMPLEX VIRUS - The present invention relates to diagnosis, prevention and treatment of Herpes simplex viruses and infection. In particular embodiments the present invention relates to methods and compositions for the prophylactic or therapeutic immunization against of infections of HSV. The present invention also relates to methods and compositions for diagnosis of the presence of and level of immunity to HSV. The invention also relates to peptide epitopes of HSV, in particular peptide epitopes of HSV2 glycoprotein D, to compositions thereof and to the use of such epitopes and compositions in methods for diagnosis, prevention and treatment of HSV. | 10-17-2013 |
20130273089 | ANTIBODY AND METHODS FOR SELECTIVE INHIBITION OF T-CELL RESPONSES - The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridomaTOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided. The present invention also provides methods of treating inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using a therapeutic amount of ex vivo expanded regulatory T-cells. | 10-17-2013 |
20130273090 | ANTIGEN-NOROVIRUS P-DOMAIN MONOMERS AND DIMERS, ANTIGEN NOROVIRUS P-PARTICLE MOLECULES, AND METHODS FOR THEIR MAKING AND USE - A substituted Norovirus capsid protein monomer, having only the P-domain, includes a foreign antigen inserted into one or more of three surface loops present on each P-domain monomer by molecular cloning. The antigen-P-domain monomer can assemble spontaneously into an octahedral, antigen-Norovirus P-particle, composed of 24 copies of the monomer. Each substituted P-domain monomer can contain one to three copies of the foreign antigen, for a total of 24-72 antigen copies on each antigen-P-particle. The antigen-P-particle is useful in methods for diagnosing, immunizing and treating individuals infected with a foreign virus and as a carrier for development of vaccines against many infectious and non-infectious diseases. The substituted monomer can be readily produced in | 10-17-2013 |
20130287807 | COMPOUNDS FOR TREATING SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE - The present invention relates to a compound comprising a peptide for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease, said peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide (Aβ). | 10-31-2013 |
20130295124 | ORF7 DEFICIENT VARICELLA VIRUS, VACCINE COMPRISING THE VIRUS AND USE THEREOF - Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus. | 11-07-2013 |
20130295125 | COMPOSITIONS AND METHODS RELATING TO MOUSE PAPILLOMA VIRUS - Methods and compositions for detecting MusPV, also known as MmuPv1, infection of a rodent subject are described according to aspects of the present invention. In specific aspects, the present invention relates to assays for detecting MusPV infection of a rodent subject; vaccine compositions for inducing an immunological response against MusPV in a rodent subject; methods of inducing an immunological response to MusPV in a rodent subject; isolated MusPV protein; isolated antibodies which specifically binds to an MusPV protein, a fragment or variant thereof; isolated recombinantly expressed MusPV proteins; expression constructs comprising a nucleic acid encoding an MusPV protein; host cells comprising the expression construct; and hybridoma cell lines expressing an anti-MusPV monoclonal antibody specific for MusPV. | 11-07-2013 |
20130295126 | VACCINES FOR INCLUSION BODY HEPATITIS - A composition comprising an isolated fowl adenovirus (FAdV), wherein the FAdV is a strain selected from FAdV-2, FAdV-7, FAdv-8a, FAdV-8b, FAdV-8a/8b or FAdV-11 serotype strains; and a suitable carrier and methods for inducing protective immunity in a subject and/or its progeny. | 11-07-2013 |
20130309262 | HSV-1 EPITOPES AND METHODS FOR USING SAME - The invention provides HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 11-21-2013 |
20130309263 | EFFECTIVE VACCINATION AGAINST PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) VIRUS PRIOR TO WEANING - The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided. | 11-21-2013 |
20130315943 | TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 58 - Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection. | 11-28-2013 |
20130315944 | INFECTIOUS GENOMIC DNA CLONE AND SEROLOGICAL PROFILE OF TORQUE TENO SUS VIRUS 1 AND 2 - The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of | 11-28-2013 |
20130323273 | Adipogenic Adenoviruses as a Biomarker for Disease - A vaccine composition may be administered to a subject to increase immunity to an adipogenic adenovirus-related cancer. The vaccine composition stimulates the production of adipogenic adenovirus neutralizing antibodies in the subject, which may increase immunity to the adipogenic adenovirus-related cancer in the subject. | 12-05-2013 |
20130337000 | VACCINES AGAINST HERPES SIMPLEX VIRUS TYPE 2: COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE - Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically. | 12-19-2013 |
20130344098 | CAT Allergen Conjugates and Uses Thereof - The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is a human allergen. In certain embodiments, the antigen is a Fel d1 antigen or a fragment thereof, covalently linked to the VLP. The invention also provides methods for producing the compositions. The compositions of the invention induce efficient immune responses, in particular antibody responses, in mammals, particularly humans. The compositions and methods of the invention are useful in the production of vaccines, in particular for the treatment and/or prevention of allergies to cat dander and other cat antigens and allergens. | 12-26-2013 |
20140010834 | NON-PATHOGENIC SEROTYPE 4 FOWL ADENOVIRUS (FADV-4) AND VIRAL VECTOR THEREOF - A high level replication fowl adenovirus (FAdV) isolate capable of reaching a viral titer of at least 3 log 10 is described. Said FAdV is a non-pathogenic strain of fowl adenovirus serotype 4, identified as FAdV-4 ON1. Additionally, the present disclosure also provides a viral vector comprising the fowl adenovirus, which has inserted an exogenous nucleotide sequence coding for at least one antigenic site of a disease of concern, as well as a method for obtaining said viral vector and an immunogenic composition comprising the same. | 01-09-2014 |
20140017269 | PROTEIN COMPLEX SYSTEM FOR INCREASED IMMUNOGENICITY AND FUNCTIONALITY, AND METHODS MAKING AND USE - Genes for proteins which spontaneously form dimers and/or oligomers can be recombinantly linked together, which upon expression in | 01-16-2014 |
20140023673 | NUCLEIC ACID MOLECULES ENCODING NOVEL HERPES ANTIGENS, VACCINE COMPRISING THE SAME, AND METHODS OF USE THEREOF - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of herpes virus antigens, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against herpes virus using the vaccines that are provided. | 01-23-2014 |
20140037665 | PESTIVIRUS SPECIES - The application relates to a | 02-06-2014 |
20140037666 | COMPOSITIONS FOR PREVENTING AND/OR TREATING AN INFECTION BY AN HIV-1 VIRUS - The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S—X1-X2-X3-K—X4-Ct (I) [SEQ ID No 1], wherein—Nt consists of a peptide having from 0 to 50 amino acids in length, —Ct consists of a peptide having from 0 to 50 amino acids in length, —each of X1 to X4 consists of an amino acid residue, wherein: —(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, —(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, —(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, —(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that—three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and—the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus. | 02-06-2014 |
20140044745 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 02-13-2014 |
20140044746 | MONOMERIC AND MULTIMERIC IMMUNOGENIC PEPTIDES - The present invention relates to novel peptides and methods for inducing an immune response in a subject against an antigen and for treatment, diagnosis and prognosis of infections or autoimmune diseases including infections with HCV, HIV, CMV and Flu. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis. | 02-13-2014 |
20140050752 | VACCINIA VIRUS POLYPEPTIDES - This document provides methods and materials related to polypeptides present in a vaccinia virus (e.g., membrane proteins such as vaccinia virus B5R, L1R, A33R, or A27L polypeptides). For example, methods for generating a vaccine comprising one or more of vaccinia virus polypeptides disclosed herein for preventing or treating Orthopoxvirus infection are provided. In addition, kits related to the use of vaccinia polypeptides are provided. | 02-20-2014 |
20140050753 | POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES - The present invention relates to the field of vaccines. In particular, the present invention provides compositions and methods relating to virus-like particle (VLP) vaccines. In one embodiment, a chimeric papillomavirus virus-like particle (VLP) comprises the L1 protein, wherein the HI loop of the L1 protein comprises negatively charged amino acids. In a more specific embodiment, a chimeric bovine papillomavirus VLP comprises the L1 protein, wherein the amino acid sequence EEEEEEEEC is inserted into the HI loop of the L1 protein. | 02-20-2014 |
20140050754 | IMMUNOGENIC CHIKUNGUNYA VIRUS PEPTIDES - The present invention relates to immunogenic peptides of Chikungunya Virus and methods for vaccinating a subject using these peptides. Also disclosed are nucleic acids encoding these peptides and methods for their production. | 02-20-2014 |
20140050755 | NOVEL H5 PROTEINS, NUCLEIC ACID MOLECULES AND VECTORS ENCODING FOR THOSE, AND THEIR MEDICINAL USE - The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals. | 02-20-2014 |
20140056933 | IMMUNOSTIMULATORY NUCLEIC ACID PACKAGED PARTICLES FOR THE TREATMENT OF HYPERSENSITIVITY - The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy. | 02-27-2014 |
20140056934 | FUSION PROTEINS AND COMBINATION VACCINES COMPRISING HAEMOPHILUS INFLUENZAE PROTEIN E AND PILIN A - The present invention relates to compositions comprising | 02-27-2014 |
20140065177 | FUSION PROTEINS AND METHODS OF USE - Compositions that include a fusion protein comprising flagellin and at least one antigen that has an isoelectric point greater than about 7.0 and that is fused to at least one domain 3 of the flagellin activate Toll-like Receptor 5. Methods of stimulating an immune response, in particular, a protective immune response include administering a composition that includes an antigen fused to a loop of domain 3 of flagellin. | 03-06-2014 |
20140065178 | Methods and Compositions for Pseudoinfectious Alphaviruses - The present invention provides pseudoinfectious alphavirus particles and methods of making them and using them to produce an immune response to an alphavirus in a subject. | 03-06-2014 |
20140065179 | ADJUVANT COMPOSITION CONTAINING CITRULLINE - A novel adjuvant composition is provided that is excellent in safety and convenience as compared to the conventional adjuvant such as Alum. An adjuvant composition comprising citrullines, which are water soluble substance present in the living body, and/or a salt thereof; a vaccine composition comprising said adjuvant composition and an antigen; a process for preparing said adjuvant composition and said vaccine composition; and a method for administering said adjuvant composition and said vaccine composition are provided. | 03-06-2014 |
20140065180 | WEST NILE VIRUS VACCINE, AND METHOD FOR PRODUCTION THEREOF - The invention provides virus-like particles (VLP) highly secreting or producing signal peptide obtained by altering a signal sequence derived from West Nile virus (WNV), the signal peptide, a WNV VLP secretion expression vector containing a nucleic acid encoding prM protein and E protein, a WNP VLP highly secreting or producing animal cell line harboring the vector, a WNV vaccine containing WNV VLP obtained by the cell line as an active ingredient, and a WNV DNA vaccine containing the VLP secretion expression vector as an active ingredient. | 03-06-2014 |
20140065181 | GENETICALLY STABLE RECOMBINANT MODIFIED VACCINIA ANKARA (RMVA) VACCINES AND METHODS OF PREPARATION THEREOF - A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine. One embodiment is directed to a fusion cytomegalovirus (CMV) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of Immediate-Early Gene-1 or Immediate-Early Gene-2 (IEfusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine. | 03-06-2014 |
20140072589 | North American Porcine Reproductive and Respiratory Syndrome (PRRS) Virus and Uses Thereof - The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided. | 03-13-2014 |
20140072590 | Compositions and Methods for the Treatment or Prevention of Human Adenovirus-36 Infection - Disclosed are fusion proteins, recombinant nucleic acid molecules, and therapeutic compositions, including yeast-based immunotherapy compositions, for use in the diagnosis, prevention and treatment of adenovirus-36 (Ad-36) infection and sequela thereof. | 03-13-2014 |
20140072591 | IPN VACCINE - The present invention relates to a live avirulent infectious pancreatic necrosis virus which has been shown to be genetically stable in biological studies. Fish exposed to said virus turn out positive for the virus without showing any signs of disease and the avirulent virus has also been shown to protect the fish against IPN for an extended period of time after administration. Thus, a vaccine comprising said virus and said virus for the prophylaxis or treatment of infectious pancreatic necrosis disease are also part of the present invention. | 03-13-2014 |
20140079725 | IMMUNE SUPPRESSOR AND ITS USE - The present invention relates to a new binder molecule useful e.g. as an immune suppressor. In particular, it has been recognized that the UL11 protein of human the cytomegalovirus, binds to the CD45 molecule, potentially altering the immune system of an individual. In addition, the present invention relates to binder molecules, in particular, fusion molecules containing the CD45 binding domain of the UL11 protein in combination with a second molecule of interest for delivery of said molecule to cells expressing the CD45 molecule. Moreover, the present invention relates to pharmaceutical compositions comprising the UL11 protein of human cytomegalovirus, or derivatives or homologs thereof, or a nucleic acid sequence encoding the same. | 03-20-2014 |
20140079726 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided. | 03-20-2014 |
20140086947 | VACCINES FOR HSV-2 - Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects. | 03-27-2014 |
20140093526 | Preparation of Neutralizing Antibody to Human Herpesvirus 6 Glycoprotein Q1 and Analysis Thereof - The present invention addresses the problem of providing a vaccine which as yet has not been provided for the disease HHV-6B, which is the cause of exanthema subitum in infants, and the problem of providing an effective screening method for other therapeutic drugs. The above-mentioned problems are solved by providing an epitope specific to HHV-6B, of the amino acid sequence (QALCEGGHVFYNP) represented by positions 484 to 496 of SEQ ID NO: 2 or a modified sequence thereof, wherein the epitope either has a sequence comprising at least five consecutive amino acids including at least E, or a sequence that preserves the 487 | 04-03-2014 |
20140093527 | COMPOSITIONS AND METHODS FOR GLIOBLASTOMA TREATMENT - The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynucleotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof. | 04-03-2014 |
20140105924 | Immunogenic HPV L2-Containing VLPs and Related Compositions, Constructs, and Therapeutic Methods - The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection. | 04-17-2014 |
20140105925 | Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Dengue Virus Infection - Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHR) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. The present invention incorporates immunoproteomics to uncover novel HLA-A2 specific epitopes derived from Dengue Virus (DV)-infected cells. These epitopes are conserved with epitope-specific CTLs cross-reacting against all four DV serotypes. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and serves as a universal vaccine candidate complementary to current vaccines. | 04-17-2014 |
20140120125 | VACCINE COMPOSITION COMPRISING AN INACTIVATED CHIKUNGUNYA VIRUS STRAIN - A vaccine composition for prophylaxis and treatment of Chikungunya virus infections is disclosed which is capable of conferring immunity against any genotypic variants of the Chikungunya virus. More particularly the invention discloses particular nucleotide sequences and their translated proteins thereof, which may be expressed as Virus Like Particles which for use as a vaccine antigens against Chikungunya virus infections. The compositions disclosed in this invention are also protective against any genotypic variants of the Chikungunya virus which may be propagated by any suitable vector of the disease including | 05-01-2014 |
20140120126 | COMPOSITIONS OF HSP60 PEPTIDES AND VIRAL ANTIGENS FOR VACCINATION AND DIAGNOSIS - The present invention provides improved vaccines comprising an isolated viral antigenic peptide and a synthetic peptide derived from a T cell epitope of HSP60. The invention includes mixtures where the peptide serves as an adjuvant as well as conjugates where the peptide is covalently linked to the viral antigen. The known synthetic peptide carrier, p458, provides significantly improved immunogenicity for synthetic viral epitopes and analogs. Ec27 is a novel peptide derived from HSP60 which increases the immunogenicity substantially of the viral antigen both as a mixture or a covalent conjugate. Some of the isolated viral epitopes are novel and are claimed for diagnostic as well as therapeutic or prophylactic uses. | 05-01-2014 |
20140127247 | VACCINES FOR HSV-2 - Compositions of recombinant HSV-2 proteins and an agonist of the innate immune system, such as an adjuvant, are provided as a vaccine. Proteins include an envelope glycoprotein and a structural protein other than an envelope glycoprotein, e.g., a capsid or tegument protein. The vaccine is for use in either HSV-2 seropositive or seronegative subjects. | 05-08-2014 |
20140127248 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H1N1 INFLUENZA - Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2011. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure. | 05-08-2014 |
20140127249 | INFLUENZA VIRUS MUTANTS AND USES THEREFOR - Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination. | 05-08-2014 |
20140134202 | VACCINES AND IMMUNOPOTENTIATING COMPOSITIONS AND METHODS FOR MAKING AND USING THEM - An immunopotentiating composition comprising a papaya mosaic virus (PapMV), or a virus-like particle (VLP) derived from PapMV coat protein, which is capable of functioning as an adjuvant and thus potentiating an immune response in an animal is provided. The immunopotentiating composition can further comprise an immunogen, which can be fused or otherwise linked to the VLP, or not linked to the VLP. The immunopotentiating composition is capable of potentiating a humoral and/or a cellular response in the animal and is suitable for use as an adjuvant or vaccine. Methods of potentiating an immune response in an animal comprising administering to the animal an immunopotentiating composition are also provided have application in both human and veterinary medicine. | 05-15-2014 |
20140134203 | Respiratory Syncytial Virus (RSV) Sequences For Protein Expression and Vaccines - The invention provides RSV fusion (F) protein ectodomain polypeptide sequences and nucleotide sequences encoding them, as well as cells containing the invention's polypeptide and nucleotide sequences. The invention further provides VLPs that contain the invention's polypeptides, and methods for using the VLPs for protein expression and vaccine formulation. Also provided are methods for distinguishing between subjects immunized with the invention's compositions and subjects infected with RSV. | 05-15-2014 |
20140134204 | METHODS OF IMPROVING VACCINE IMMUNOGENICITY - The present invention provides a process called “Immune Banking” that enhances vaccine efficacy by exploiting existing humoral responses. The process involves tagging new antigens with molecular markers recognized by an existing antibody response. This recognition of the tagged vaccine components enhances adaptive immune responses to the new vaccine. | 05-15-2014 |
20140147457 | RECOMBINANT HVT VECTORS EXPRESSING ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF - The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors. | 05-29-2014 |
20140147458 | NOVEL VARICELLA-ZOSTER VIRUS STRAINS, AND CHICKEN POX AND HERPES ZOSTER VIRUS VACCINE USING SAME - The present invention relates to novel Varicella-zoster virus strain and to a chicken pox and herpes zoster virus vaccine using the same. More particularly, the present invention relates to genome DNA of VZV MAV/06 strain isolated from a Korean patient, to an open reading frame (ORF) thereof, to a protein coded by the genome DNA of VZV MAV/06 strain and the ORF thereof, and to a vaccine composition which contains the protein as an active ingredient. | 05-29-2014 |
20140147459 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H1N1 INFLUENZA - Described herein is the generation of optimized H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to H1N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on selected H1N1 viruses isolated from 1918-2012. Provided herein are optimized H1N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure. | 05-29-2014 |
20140147460 | TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 33 - The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein and the virus-like particle are useful for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. The invention also relates to the use of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. | 05-29-2014 |
20140154282 | CONJUGATES UTILIZING PLATFORM TECHNOLOGY FOR STIMULATING IMMUNE RESPONSE - Templated conjugates created from naturally-occurring protein sequences found in pathogens, such as viruses, are disclosed. The sequences are “templated” into a consensus coiled-coil sequence in a platform in order to form a two-stranded antigen suitable for immunization of a subject. | 06-05-2014 |
20140154283 | IDENTIFICATION OF A WEST NILE VIRUS CD4 T CELL EPITOPE AND USE THEREOF - Described herein is the identification and of a potent West Nile virus (WNV) CD4 positive T cell epitope and its use for increasing the immunogenicity of heterologous flavivirus vaccines, such as dengue virus type 2 (DENV-2) DNA and virus-like particle (VLP) vaccines. Also described are methods for the identification of potent T cell epitopes to enhance immunogenicity of multivalent vaccines. | 06-05-2014 |
20140154284 | METHODS AND COMPOSITIONS FOR INHIBITING POLYOMAVIRUS-ASSOCIATED PATHOLOGY - Disclosed herein are methods of eliciting an immune response against a polyomavirus (for example, BKV serotype I (BKV-I), BKV serotype II (BKV-II), BKV serotype III (BKV-III) and/or BKV serotype IV (BKV-IV)) and methods of treating or inhibiting polyomavirus-associated pathology (such as polyomavirus-associated nephropathy, BKV-associated hemorrhagic cystitis, or JC virus-associated progressive multifocal leukoencephalopathy; PML). Further disclosed are immunogenic compositions of use in the disclosed methods. Also disclosed are methods of selecting an organ transplant donor and/or recipient including detecting whether the prospective donor and/or recipient has BKV serotype-specific (such as BKV serotype IV-specific) neutralizing antibodies. | 06-05-2014 |
20140161833 | NOVEL NEUTRALIZING IMMUNOGEN (NIMIV) OF RHINOVIRUS AND ITS USES FOR VACCINE APPLICATIONS - The invention relates to methods and compositions for preventing or treating human rhinovirus infection. | 06-12-2014 |
20140170180 | PORCINE PARVOVIRUS 5A, METHODS OF USE AND VACCINE - The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus. | 06-19-2014 |
20140170181 | VACCINE AGAINST WHITE SPOT SYNDROME VIRUS - A vaccine against White Spot Syndrome Baculovirus Complex infection in penaeid shrimp comprises algae expressing peptides having at least 70% similarity of amino acid sequence Seq No. 1, wherein the vaccine is administered to the penaeid shrimp as food additive. | 06-19-2014 |
20140178419 | RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPS) - The present invention is generally related to virus-like particles (VLPs) comprising rabies virus (RV) glycoproteins (G proteins) and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of rabies virus infection. | 06-26-2014 |
20140178420 | Treatment of Inflammation, Autoimmune, and Neurodegenerative Disorders with Immunosuppressive Tat Derivative Polypeptides - The present specification provides immunosuppressive Tat derivative polypeptides, compositions, and methods of using such polypeptides and compositions to treat an autoimmune disease, an inflammation-associated disease and/or a neurodegenerative disease. | 06-26-2014 |
20140178421 | Use of Native Peptides and Their Optimized Derivatives For Vaccination - The present invention pertains to the field of vaccination, and more particularly to the fields of antitumor and antiviral vaccination. The invention relates to the use of a native peptide in a medicinal composition, for selecting and/or boosting part of a CTL immune response which has been initiated by an optimized immunogenic peptide derived from said native peptide. The invention also concerns vaccination kits which comprise several doses of optimized peptides and of their cognate native peptides. | 06-26-2014 |
20140186382 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST HUMAN CYTOMEGALOVIRUS INFECTION - The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators. | 07-03-2014 |
20140193446 | BIODEGRADABLE HIGH-EFFICIENCY DENGUE VACCINE, METHOD FOR MAKING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention is related to a biodegradable high-efficiency dengue vaccine, a method for making the same, and a pharmaceutical composition comprising the same. The biodegradable high-efficiency dengue vaccine comprises a biodegradable nanocomplex with electric properties holding a dengue viral protein inside. An organism has antibody responses after vaccination with the biodegradable nanocomplex twice. Accordingly, in comparison with the Alum adjuvant and Ribi adjuvant used in the traditional dengue vaccine of the prior art, the vaccination times in the present invention is decreased to further reduce the vaccination cost, so the biodegradable high-efficiency dengue vaccine is good for being a commercial vaccine. | 07-10-2014 |
20140193447 | FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS) - The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof. | 07-10-2014 |
20140193448 | VACCINE AGAINST MULTITYPES OF AVIAN INFLUENZA VIRUSES AND USES THEREOF - The present invention relates to a recombinant DNA molecule encoding a mutated hemagglutinin protein, wherein the mutated hemagglutinin protein consists of the amino acid sequence of SEQ ID NO: 2 with one or more mutations at amino acid residue selecting from the group consisting of residue 83, 127, 138 and the combination thereof. The present invention also relates to a composition comprising the recombinant DNA molecule as described above and a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle. The present invention further relates to a kit for prime-boost vaccination, comprising at least a composition comprising a recombinant DNA molecule as described above and at least a composition for the boost-vaccination comprising a recombinant hemagglutiinin protein or a virus-like particle, wherein the recombinant hemagglutiinin protein is the corresponding hemagglutiinin protein encoded by the recombinant DNA molecule. The present invention still further relates to a method of vaccinating a subject susceptible to avian influenza comprising administrating to the subject an effective amount of the composition as described above. The present invention still further relates to a recombinant hemagglutinin protein consisting of the amino acid sequence of SEQ ID NO: 2 with one or more mutations at amino acid residue selecting from the group consisting of residue 83, 127, 138, and the combination thereof. | 07-10-2014 |
20140199337 | INFLUENZA H5 VACCINES - The present invention is based on the surprising finding that H5 protein of clade 1 H5N1 induces, in particular by a single-shot vaccination, a cross-clade protective immune response to influenza viruses with H5N1 HA. In one aspect, the invention is thus directed to H5 protein of clade 1 H5N1 virus for use in a method of treating or preventing infections with H5N1 virus of a different clade, namely of a clade different from clade 1 or from any clade with the exception of clade 1, respectively. | 07-17-2014 |
20140205620 | ENGINEERED RESPIRATORY SYNCYTIAL VIRUSES WITH CONTROL OF CELL-TO-CELL VIRUS TRANSMISSION FOR ENHANCED SAFETY OF LIVE VIRUS VACCINES - Highly antigenic yet safe vaccines against diseases caused by | 07-24-2014 |
20140205621 | CANINE CORONAVIRUS VACCINE - A new pantropic canine coronavirus (CCoV) strain, having reduced pathogenicity, and capable of eliciting an immune response, is described. | 07-24-2014 |
20140205622 | VACCINES AGAINST INFLUENZA VIRUS - Disclosed are immunogenic conjugates having the general formula: | 07-24-2014 |
20140212447 | Rift Valley Fever Virus Glycoproteins, GN and GC, and their Use - The present invention describes subunit vaccines containing Gn and Gc glycoproteins of the Rift Valley Fever Virus, including nucleic acids encoding such glycoproteins, host cells, vectors, and immunoreagents generated with the glycoproteins, methods of vaccination, methods of diagnosis, and kits. | 07-31-2014 |
20140220060 | HIV-1 SOUTH AFRICAN SUBTYPE C ENV PROTEINS - The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polypeptides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations of immunogenic compositions and uses thereof. | 08-07-2014 |
20140220061 | YEAST EXPRESSION OF FLAVIVIRUS VIRUS-LIKE PARTICLES AND USE THEREOF - Described herein is a method for the production of flavivirus virus-like particles (VLPs) in a yeast system. In some cases, flavivirus structural proteins are expressed in a | 08-07-2014 |
20140220062 | CONDITIONAL REPLICATING CYTOMEGALOVIRUS AS A VACCINE FOR CMV - The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the invention can be used to treat and/or prevent primary CMV infection, infection due to reactivation of a latent CMV and a super-infection of a different strain of CMV that had been previously encountered. The present invention also relates to a replication defective CMV which has been recombinantly altered to allow for external control of viral replication. Compositions comprising the replication defective CMV are also encompassed by the present invention. | 08-07-2014 |
20140234354 | PORCINE PARVOVIRUS 5B, METHODS OF USE AND VACCINE - The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus. | 08-21-2014 |
20140234355 | INFECTIOUS CLONES OF TORQUE TENO VIRUS - The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen. | 08-21-2014 |
20140234356 | INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS - The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans. | 08-21-2014 |
20140234357 | H5 PROTEINS OF H5N1 INFLUENZA VIRUS FOR USE AS A MEDICAMENT - The present invention is based on the surprising finding that H5 protein of clade 1 H5N1 induces, in particular by a single-shot vaccination, a cross-clade protective immune response to influenza viruses with H5N1 HA. In one aspect, the invention is thus directed to H5 protein of clade 1 H5N1 virus for use in a method of treating or preventing infections with H5N1 virus of a different clade, wherein the H5N1 virus of a different clade comprises a particular polynucleotide and/or H5 protein. | 08-21-2014 |
20140234358 | NEWCASTLE DISEASE VIRUS VECTORED AVIAN VACCINES - The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease. | 08-21-2014 |
20140234359 | PLANT VIRAL VACCINES AND THERAPEUTICS - The invention relates to methods and related products for preventing and treating disease, based on the use of plant viral vaccines and plant viral defense strategies. The methods also involve the identification of appropriate therapeutic strategies for diseases such as cancers. | 08-21-2014 |
20140234360 | INFLUENZA VACCINE - Disclosed are immunogenic conjugates having the general formula: HA2-XXX-Pr, where HA2 is the influenza HA2 fusion peptide or a portion thereof, XXX is a linker and Pr is the carrier. Methods of producing an immune response in a subject using the disclosed immunogenic conjugates, as well as methods of treating, ameliorating or preventing influenza infection, are also disclosed. | 08-21-2014 |
20140242102 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 08-28-2014 |
20140242103 | COMPOSITION - The present invention provides a modified influenza virus wherein the RNA of the haemagglutinin gene has been modified such that the haemagglutinin signal sequence is not expressed and the virus produces a haemagglutinin protein that lacks a functional signal sequence. The invention further provides composition comprising the modified virus and uses of the modified virus. | 08-28-2014 |
20140242104 | SELF-ASSEMBLING PEPTIDE NANOPARTICLES AS VACCINES AGAINST INFECTION WITH NOROVIRUS - Self-assembling peptide nanoparticles (SAPN) incorporating T-cell epitopes and displaying the P domain of the norovirus protein VP1 are described. The nanoparticles of the invention consist of aggregates of a continuous peptide chain comprising two coiled coil oligomerization domains connected by a linker segment wherein one or both oligomerization domains incorporate T-cell epitopes within their peptide sequence. These nanoparticles are useful as vaccines and adjuvants for the prevention and treatment of norovirus infections. | 08-28-2014 |
20140255438 | FUSION PROTEINS AND METHODS OF USE - Compositions that include a fusion protein comprising flagellin and at least one antigen that has an isoelectric point greater than about 7.0 and that is fused to at least one domain 3 of the flagellin activate Toll-like Receptor 5. Methods of stimulating an immune response, in particular, a protective immune response include administering a composition that includes an antigen fused to a loop of domain 3 of flagellin. | 09-11-2014 |
20140255439 | VIRUS-LIKE PARTICLES AND PROCESS FOR PREPARING SAME - An in vitro process of preparing virus-like particles (VLPs) from recombinant papaya mosaic virus coat protein and ssRNA, which allows for large scale production of VLPs in high yields, is provided. Also provided are VLPs comprising ssRNA prepared by the in vitro process. The VLPs can be used as adjuvants and when fused to an antigen, as vaccines. The use of the VLPs for stimulation of the innate immune response is also provided. | 09-11-2014 |
20140255440 | RECOMBINANT VIRAL VECTORS AND METHODS FOR INDUCING AN IMMUNE RESPONSE TO YELLOW FEVER VIRUS - The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to yellow fever virus. The invention provides recombinant viral vectors based on the non-replicating modified vaccinia virus Ankara or based on a D4R-defective vaccinia virus. When administered according to methods of the invention, the recombinant viral vectors induce a broad immune response to yellow fever virus and demonstrate an excellent safety profile. | 09-11-2014 |
20140255441 | VLPS CONTAINING LIGANDS AND METHODS RELATED THERETO - This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a TLR5 agonist on the exterior without an antigen. | 09-11-2014 |
20140255442 | NOVEL EUROPEAN PRRSV STRAIN - The present invention is related to improved modified live PRRS vaccines containing new PRRSV European strains of PRRSV and methods of use and manufacture of such vaccines. | 09-11-2014 |
20140271696 | Heat-Stable Respiratory Syncytial Virus F Protein Oligomers and Their Use in Immunological Compositions - Heat-stable oligomeric recombinant polypeptides, presenting at least one antigenic epitope of the pre-fusion Respiratory Syncytial Virus (RSV) F protein, comprising the RSV F protein ectodomain, functionally deleted in the HRB region, transmembrane and cytoplasmic domains replaced with a heterologous trimerization domain, and absent two functional multibasic furin cleavage sites, are useful as antigenic components in immunogenic compositions useful in methods of inducing an immune response and vaccinate against RSV infections. | 09-18-2014 |
20140271697 | ENHANCED EXPRESSION OF PICORNAVIRUS PROTEINS - The disclosure provides fusion proteins containing N-terminal signal peptides fused to immunogenic polypeptides. The immunogenic polypeptides may be from viruses, bacteria, or fungi. The disclosure also provides elevated expression of the immunogenic polypeptides using the N-terminal signal peptide. The N-terminal signal peptides enhance synthesis of the protein, particularly where the protein is neither a secretory nor a transmembrane peptide. The fusion proteins may be used to diagnose disease and to induce immune responses. | 09-18-2014 |
20140271698 | PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS, COMPOSITIONS, VACCINE AND METHODS OF USE - The present invention relates to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) mutant strains having increased stability; compositions containing the strains or antigens derived therefrom; vaccines containing the strains, including killed, attenuated or subunit vaccines; nucleic acids encoding PRRSV polypeptides, polypeptides encoded by the nucleic acids, including antigenic fragments thereof; antibodies which specifically bind to said polypeptides, and methods making and using thereof. | 09-18-2014 |
20140286977 | Protein F - A Novel Haemophilus Influenzae Adhesin with Laminin and Vitronectin binding Properties - A vaccine composition comprising a protein, which can be detected in | 09-25-2014 |
20140286978 | CYTOTOXIC T LYMPHOCYTE INDUCER - The invention provides a cytotoxic T lymphocyte inducer comprising a virus-like particle composed of VP1 of simian virus 40. The T cell epitope peptide is inserted into a DE loop and/or an HI loop of the VP1. | 09-25-2014 |
20140286979 | CANINE INFLUENZA RECOMBINANT VIRUS, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - A canine influenza recombinant virus includes HA and NA genes of ZJCIV canine influenza virus as well as six internal genes PA, PB1, PB2, M, NP and NS of a PR8 virus. The nucleotide sequence of the HA gene is selected from the group consisting of: (1) a nucleotide sequence encoding an amino acid sequence of SEQ ID NO.1; (2) a nucleotide sequence encoding an amino acid sequence which has at least 98% sequence identity to the amino acid sequence of SEQ ID NO.1. The nucleotide sequence of the NA gene is selected from the group consisting of: (1) a nucleotide sequence encoding an amino acid sequence of SEQ ID NO.2; (2) a nucleotide sequence encoding an amino acid sequence which has at least 98% sequence identity to the amino acid sequence of SEQ ID NO.2. | 09-25-2014 |
20140286980 | INFECTIOUS CLONES OF TORQUE TENO VIRUS - The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length TTV genomes that can replicate efficiently in host animals and tissue culture. | 09-25-2014 |
20140286981 | BROADLY REACTIVE MOSAIC PEPTIDE FOR INFLUENZA VACCINE - The invention provides for mosaic influenza virus HA and NA sequences and uses thereof. | 09-25-2014 |
20140286982 | MULTIMERIC MULTIEPITOPE INFLUENZA VACCINES - An isolated polynucleotide encoding an influenza multi-epitope polypeptide, wherein the multi-epitope polypeptide comprises multiple copies of a plurality of influenza virus peptide epitopes wherein the polypeptide is B(X | 09-25-2014 |
20140286983 | DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES - Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus. | 09-25-2014 |
20140294879 | MODIFIED RSV F PROTEINS AND METHODS OF THEIR USE - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 10-02-2014 |
20140302076 | IMMUNOGENIC COMPOSITIONS AND METHODS THEREFOR - The present invention provides compositions relating to viral capsomeres which comprise foreign immunogenic sequences for use in pharmaceutical compositions and methods of producing such compositions, and related isolated or purified protein and nucleic acid molecules, vectors, host cells, compositions, and methods of use to augment an immune response, immunise an animal and prophylactically or therapeutically treat a disease, disorder or condition. The viral capsomere may be derived from a polyomavirus and comprise an immunogen of interest at the N-terminus and further at the C-terminus and/or at one or more exposed loops of the capsomere. | 10-09-2014 |
20140302077 | LIVE ATTENUATED INFLUENZA VIRUS - Provided are live attenuated influenza A and B viruses as well as a composition, influenza A and B genes, a vector with a respective gene, a host cell comprising such vector, a method for preparing a live attenuated influenza A or B virus and a use of the influenza viruses as a vaccine. An influenza A virus contains a NP-gene, which includes a silent mutation at one or more positions selected from nucleotide 1467, nucleotide 1473, nucleotide 1500, nucleotide 1503, nucleotide 1512, nucleotide 1515, nucleotide 1518, nucleotide 1521, and nucleotide 1524 of SEQ ID No: 1. A PA gene includes a silent mutation at one or more positions corresponding to a position selected from nucleotides 2100 and 2103 of SEQ ID No: 3. | 10-09-2014 |
20140302078 | HAEMOPHILUS INFLUENZAE TYPE B - Polypeptides comprising various amino acid sequences derived from | 10-09-2014 |
20140302079 | NOVEL INFLUENZA HEMAGGLUTININ PROTEIN-BASED VACCINES - Novel vaccines are provided that elicit broadly neutralizing anti-influenza antibodies. Some vaccines comprise nanoparticles that display hemagglutinin trimers from influenza virus on their surface. The nanoparticles comprise fusion proteins comprising a monomeric subunit of ferritin joined to at least a portion of an influenza hemagglutinin protein. Some portions comprise the ectodomain while some portions are limited to the stem region. The fusion proteins self-assemble to form the hemagglutinin-displaying nanoparticles. Some vaccines comprise only the stem region of an influenza hemagglutinin protein joined to a trimerization domain. Such vaccines can be used to vaccinate an individual against infection by heterologous influenza viruses and influenza virus that are antigenically divergent from the virus from which the nanoparticle hemagglutinin protein was obtained. Also provided are fusion proteins and nucleic acid molecules encoding such proteins. | 10-09-2014 |
20140308307 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 10-16-2014 |
20140308308 | COMPOSITIONS AND METHODS FOR TREATMENT OF CYTOMEGALOVIRUS - The present disclosure provides compositions and methods useful for treating HCMV infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (VLPs) which comprise one or more Moloney Murine leukemia virus (MMLV) core proteins and include one or more HCMV epitopes, such as, for example, from HCMV envelope glycoproteins gB and/or gH and/or tegument protein pp65. Among other things, the present invention encompasses the recognition that a combination of antigens (e.g., envelope glycoproteins and structural proteins) can lead to beneficial immune responses, for example that include both a humoral response (e.g., production of neutralizing antibodies) and a cellular response (e.g., T-cell activation). | 10-16-2014 |
20140322255 | SECOND GENERATION VIRUS-LIKE PARTICLES (VLP) FROM EPSTEIN-BARR VIRUSES FOR VACCINATION PURPOSES - The present invention relates to an Epstein-Barr virus-like particle (EB-VLP) substantially free of Epstein-Barr Virus (EBV) DNA. The present invention also relates to a polynucleotide comprising an EBV genome a) lacking at least one expressible gene selected from the group consisting of the BFLF1 gene, the BBRF gene, the BGRF1 gene, the BDRF1 gene, the BALF3 gene, the BFRF1A gene, and the BFRF1 gene, and b) producing the EB-VLP of the invention in a suitable host cell. The present invention further relates to a vector and a host cell comprising the polynucleotide of the invention as well to a method of manufacturing said EB-VLPs, a method of manufacturing a vaccine thereof, a vaccine and a composition comprising said EB-VLPs. | 10-30-2014 |
20140328870 | NUCLEIC ACID VACCINES AGAINST HERPES SIMPLEX VIRUS TYPE 2: COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE - Herpes Simplex Virus-2 (HSV-2) infection is a major health concern. The present disclosure provides, inter alia, certain highly effective vaccines and immunogenic compositions against HSV-2. The antigens can be used therapeutically or prophylactically. | 11-06-2014 |
20140335115 | SUPPRESSORS OF MATURE T CELLS - Disclosed herein is a viral polypeptide and homologs thereof that inhibit an immune response, particularly the response of memory and effector CD4 | 11-13-2014 |
20140335116 | AVOIDING NARCOLEPSY RISK IN INFLUENZA VACCINES - The invention provides influenza vaccines and methods which improve the safety of influenza vaccines further, in particular in relation to the risk of causing narcolepsy in adjuvanted vaccines. | 11-13-2014 |
20140335117 | Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses - The present invention relates to enveloped RNA viruses. The invention in particular relates to the generation of superior antigens for mounting an immune response by first identifying then mutating the immunosuppressive domains in fusion proteins of enveloped RNA viruses resulting in decreased immunosuppressive properties of viral envelope proteins from the viruses. | 11-13-2014 |
20140335118 | SYNTHETIC PEPTIDE-BASED MARKER VACCINE AND DIAGNOSTIC SYSTEM FOR EFFECTIVE CONTROL OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) - A peptide-based marker vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS) and a set of immunodiagnostic tests for the prevention, monitoring and control of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) are disclosed. Vaccine formulations according to various embodiments of the invention contain a mixture of peptides derived from PRRSV GP2, GP3, GP4, or GP5 proteins; each peptide individually contains a B cell PRRSV neutralizing/receptor binding epitope which is individually linked to an artificial T helper epitope for enhancement of the respective peptide's immunogenicity; and which can be supplemented with a mixture of peptides representing the T helper epitopes derived from the PRRSV GP4, GP5, M and Nucleocapsid proteins to provide cell mediated immunity. Such viral peptide compositions are prepared in an acceptable delivery system as vaccine formulations and can provide cross protection of PRRSV antibody free pigs from infection upon PRRSV challenge. | 11-13-2014 |
20140348863 | CMV ANTIGENS AND USES THEREOF - The present invention relates to immunogenic compositions comprising CMV antigens and methods for preparing compositions that contain CMV antigens. The invention also relates to methods for inducing an immune response to CMV. | 11-27-2014 |
20140348864 | PORCINE CIRCOVIRUS TYPE-2 (PCV2) SUBUNIT VACCINE - A procine circovirus type-2 (PCV2) immunogenic composition includes an antigenic peptide. The antigenic peptide is a non-arginine-rich peptide of a PCV2 open reading frame 2 (ORF2) and/or a recombinant fusion protein having the non-arginine-rich peptide of the PCV2 ORF2, a PE peptide, and a KDEL signal peptide. The number of arginines of the non-arginine-rich peptide of the PCV2 ORF2 is not greater than half of the number of arginines of the arginine-rich domain of the N terminal of the PCV2 ORF2. | 11-27-2014 |
20140356388 | Vaccine - Screening Method - The present invention provides screening methods which may be regarded as in vitro or ex vivo methods of interrogating the immune system to understand what viral antigens are “seen” and responded to by T cells of the immune systems during viral infection. The screening methods further link in vitro or ex vivo responses to progression of infection in subjects. | 12-04-2014 |
20140363458 | MALARIA VACCINE - The present invention provides a particle comprising a polypeptide and at least one malaria antigen, and a composition or vaccine comprising thereof, its use in medicine, particularly in the prevention or treatment of malaria infections. | 12-11-2014 |
20140363459 | SYNTHETIC CAPSID PROTEINS AND USES THEREOF - The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic Circovirus type capsid proteins with improved properties. These proteins, or the coding nucleic acids, are useful e.g., to generate antibodies, immunogen compositions, or vaccines. The invention further relates to methods for treating and/or preventing PCV2-associated diseases in mammals using said proteins, nucleic acids or compositions. The invention also relates to compositions and methods for detecting PCV2 in a sample, using the above proteins, nucleic acids, or antibodies. | 12-11-2014 |
20140363460 | COMBINED ANTIGEN AND DNA VACCINE FOR PREVENTING AND TREATING RSV INFECTION - The present disclosure relates to treating and preventing symptoms of respiratory syncytial virus (RSV) infection using a combination vaccine containing an RSV antigen and a DNA encoding the RSV antigen. | 12-11-2014 |
20140370041 | COMPOSITIONS AND METHODS FOR TREATING INFLUENZA - The present application provides compositions and methods useful for treating influenza. As described herein, the compositions and methods are based on the development of peptides and peptide combinations which exhibit immunogenic properties against influenza. In some embodiments, the peptide combinations induce a protective response against multiple strains of influenza, e.g., seasonal strains of influenza or even the new pandemic influenza A (H1N1) virus of swine origin. | 12-18-2014 |
20140370042 | Stabilized Antiviral Fusion Helices - Internally cross-linked peptides useful for interfering with Respiratory Syncytial Virus (RSV) infection is based on RSV-F protein. These peptides are capable of reducing infection in cellular and animal models. | 12-18-2014 |
20140370043 | VESICULAR STOMATITIS VIRUS FOR PRIME BOOST VACCINE - The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position ( | 12-18-2014 |
20140370044 | MODIFIED EPITOPES FOR BOOSTING CD4+ T-CELL RESPONSES - The present invention relates to immunogenic peptides comprising a T-cell epitope. Said peptides are modified such that CD4+ T-cell responses are obtainable that are much stronger than the CD4+ T-cell responses obtained with the same peptides not comprising said modification. In particular, the modification is the addition of a cysteine, insertion of a cysteine or mutation into a cysteine of a residue at a position adjacent to but outside the MHC-binding site of the peptide. Further disclosed are the use of such modified peptides in treating, suppressing or preventing diseases such as infectious or allergic diseases and autoimmune diseases, in preventing or suppressing graft rejection, or in the eradication of tumor cells. | 12-18-2014 |
20140377295 | INFLUENZA VACCINES CONTAINING MODIFIED ADENOVIRUS VECTORS - This disclosure provides universal influenza vaccines which can provide extended protection for several years, provide improved protection to circulating influenza strains that were not predicted accurately for annual vaccine manufacturing, and provide protection against newly emerging strains of influenza virus which carry the potential for establishing global pandemics. | 12-25-2014 |
20140377296 | H3 INFLUENZA A VIRUS - The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof. | 12-25-2014 |
20140377297 | RECOMBINANT PROTEINS OF PARAPOXVIRUS OVIS AND PHARMACEUTICAL COMPOSITIONS THEREFROM - The invention relates to polynucleotides coding for the PPVO viral genome, to fragments of the polynucleotides coding for the PPVO genome and to polynucleotides coding for individual open reading frames (ORFs) of the PPVO viral genome. The invention also relates to recombinant proteins expressed from the above mentioned polynucleotides and to fragments of said recombinant proteins, and to the use of said recombinant proteins or fragments for the preparation of pharmaceutical compositions. | 12-25-2014 |
20140377298 | TREATMENT OF PIGS WITH PCV2 ANTIGEN - The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets. | 12-25-2014 |
20150017194 | VIRUS LIKE PARTICLE COMPRISING PD-1 ANTIGEN OR PD-1 LIGAND ANTIGEN - The present invention provides a virus like particle comprising a virus structural protein and an antigen derived from PD-1 or a ligand of PD-1, and a composition or kit comprising thereof, its use in immune response etc. | 01-15-2015 |
20150017195 | PORCINE KNOB XENOTYPE CHIMERIC ADENOVIRAL VECTOR FOR DENDRITIC CELL INFECTION - Disclosed are methods of transforming dendritic cells with a chimeric adenovirus-5 (Ad5). A chimeric adenovirus includes a fiber comprising a tail, a shaft and a knob, wherein the knob is a porcine knob, and a nucleic acid comprising a promoter operably linked to a heterologous sequence encoding an antigen peptide. | 01-15-2015 |
20150017196 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H5N1 AND H1N1 INFLUENZA VIRUSES - Described herein is the generation of optimized H5N1 and H1N1 influenza HA polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on H5N1 and H1N1 influenza isolates. Provided herein are optimized H5N1 and H1N1 influenza HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure. | 01-15-2015 |
20150023995 | VIRUS-LIKE PARTICLES COMPRISING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR ENHANCED CROSS REACTIVITY - The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed. | 01-22-2015 |
20150023996 | POLYNUCLEOTIDES FOR TREATING ONCOGENIC VIRAL POLYPEPTIDE POSITIVE TUMORS - This document relates to polynucleotides encoding antigenic polypeptides to induce an immune response to oncogenic viral polypeptides. Also provided are compositions comprising polynucleotides encoding antigenic polypeptides, and methods of use. In the provided methods, the virus can be a human papilloma virus. In some embodiments, a method for killing a cell expressing a first oncogenic viral polypeptide in a subject is provided. The method includes administering to the subject a composition in an amount sufficient to initiate an immune response against the first oncogenic viral peptide, where the composition comprises a pharmaceutically acceptable carrier and a polynucleotide provided herein and the immune response is effective to cause a cytotoxic effect in the cell. In some embodiments, the polynucleotide includes a second nucleotide sequence encoding a second antigenic polypeptide. The first oncogenic viral polypeptide can be E6 and the second oncogenic viral polypeptide can be E7. | 01-22-2015 |
20150030622 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS - In some embodiments, the present invention provides respiratory syncytial virus (RSV) F proteins, polypeptides and protein complexes that comprise one or more cross-links to stabilize the protein, polypeptide or protein complex in its pre-fusion conformation. In some embodiments the present invention provides RSV F proteins, polypeptides and protein complexes comprising one or more mutations to facilitate such cross-linking. In some embodiments the present invention provides compositions comprising such proteins, polypeptides or protein complexes, including vaccine compositions, and methods of making and using the same. | 01-29-2015 |
20150037364 | ADENOVIRUSES AND THEIR USE - Baboon Adenovirus (BaAdV)-2/4 and BaAdV-3 are disclosed herein. BaAdV-2/4 and BaAdV-3 polynucleotide, polypeptides and antibodies that specifically bind BaAdV-2/4 and/or BaAdV-3 are disclosed. Methods are disclosed for detecting BaAdV-2/4 and BaAdV-3. Methods are also disclosed for treating, preventing, and inducing an immune response to BaAdV-2/4 and/or BaAdV-3. Kits are also provided. | 02-05-2015 |
20150044247 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H3N2, H2N2, AND B INFLUENZA VIRUSES - Described herein is the generation of optimized H3N2, H2N2 and B influenza HA polypeptides for eliciting a broadly reactive immune response to influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on H3N2, H2N2 and B influenza isolates. Provided herein are optimized H3N2, H2N2 and B influenza HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure. | 02-12-2015 |
20150044248 | POLYPEPTIDES AND THEIR USE IN TREATING METAPNEUMOVIRUS (MPV) INFECTION - Polypeptides and compositions thereof are provided for treating or limiting metapneumovirus (MPV) infection, as well as methods for designing such polypeptides. In further aspects, methods of using said isolated polypeptides, VLPs or pharmaceutical compositions are provided, which include methods for treating a metapneumovirus (MPV) infection, methods for limiting development of an MPV infection, methods for generating an immune response in a subject, methods for monitoring an MPV-induced disease in a subject and/or monitoring response of the subject to immunization by an MPV vaccine, methods for detecting MPV binding antibodies, methods for producing MPV antibodies, and methods of preventing an MPV infection. | 02-12-2015 |
20150050305 | HENDRA AND NIPAH VIRUS G GLYCOPROTEIN IMMUNOGENIC COMPOSITIONS - Immunogenic compositions directed against Hendra and/or Nipah viruses, and methods of its use, are provided. In addition, methods of distinguishing subjects vaccinated with the immunogenic compositions of the invention from those infected with Hendra and/or Nipah virus are provided. | 02-19-2015 |
20150050306 | Epitope-Scaffold Immunogens Against Respiratory Syncytial Virus (RSV) - The present invention provides polypeptides and compositions thereof for treating or limiting respiratory syncytial virus infection, and computational methods for designing such polypeptides. | 02-19-2015 |
20150050307 | MATERIALS AND METHODS FOR PRODUCING IMPROVED LENTIVIRAL VECTOR PARTICLES - Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided. | 02-19-2015 |
20150050308 | CORONAVIRUS, NUCLEIC ACID, PROTEIN, AND METHODS FOR THE GENERATION OF VACCINE, MEDICAMENTS AND DIAGNOSTICS - A new coronavirus is disclosed herein with a tropism that includes humans. Means and methods are provided for diagnosing subjects (previously) infected with the virus. Also provided are among others vaccines, medicaments, nucleic acids and specific binding members. | 02-19-2015 |
20150056230 | Equine Encephalitis Virus Vaccines and Methods of Using Thereof - Disclosed herein are nucleotide sequences which encode a plurality of structural proteins, except the capsid, of an equine encephalitis virus, wherein the nucleotide sequence is codon-optimized for mammalian expression. The nucleotide sequences are codon-optimized for expression in humans. As disclosed herein, the nucleotide sequences confer protection against Venezuelan equine encephalitis virus (VEEV), western equine encephalitis virus (WEEV), and/or eastern equine encephalitis virus (EEEV). | 02-26-2015 |
20150056231 | RECOMBINANT PAPAYA MOSAIC VIRUS COAT PROTEINS AND USES THEREOF IN INFLUENZA VACCINES - Recombinant papaya mosaic virus (PapMV) coat proteins comprising one or more antigenic peptides derived from an influenza virus antigen, such as from the M2e peptide, fused at a position within a predicted random coil within 13 amino acids of the N-terminus of the coat protein, uses thereof to prepare virus-like particles (VLPs), and uses of the VLPs in influenza vaccines. | 02-26-2015 |
20150056232 | RECOMBINANT BACTERIUM FOR INDUCTION OF CELLULAR IMMUNE RESPONSE - The present invention provides a recombinant bacterium and methods of using the recombinant bacterium to induce a cellular immune response. | 02-26-2015 |
20150056233 | INFLUENZA HEMAGGLUTININ PROTEINS AND METHODS OF USE THEREOF - In some embodiments the present invention provides influenza hemagglutinin (“HA”) polypeptides, proteins, and protein complexes that comprise a stalk domain that is engineered to facilitate maintenance of its native trimeric conformation, even if the head domain of the HA protein is removed or disrupted. In some embodiments, the present invention provides compositions comprising such polypeptides, proteins, and protein complexes, and methods of use of such proteins and compositions, for example as vaccine immunogens. | 02-26-2015 |
20150056234 | HPV EPITOPES TARGETED BY T CELLS INFILTRATING CERVICAL MALIGNANCIES FOR USE IN VACCINES - The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B. | 02-26-2015 |
20150056235 | MATERIALS AND METHODS FOR RESPIRATORY DISEASE CONTROL IN CANINES - The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention. | 02-26-2015 |
20150056236 | AN INFECTIOUS cDNA CLONE OF NORTH AMERICAN PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) VIRUS AND USES THEREOF - The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS virus, RNA molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules. Also provided are isolated polynucleotide molecules further comprising at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope, and vaccines comprising North American PRRS virus, RNA molecules, plasmids and viral vectors comprising such isolated polynucleotide molecules. | 02-26-2015 |
20150079121 | Human Respiratory Syncytial Virus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using Same - Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode an RSV immunogen are disclosed. Nucleic acid are disclosed that comprise the sequences that encodes consensus RSV F protein or immunogenic fragment thereof, sequences that encodes an RSV G(A) protein or immunogenic fragment thereof and sequences that encodes an RSV G(B) protein or immunogenic fragment thereof. Compositions comprising one, combinations of two or all three sequences are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Nucleic acid molecules and compositions comprising the chemokine CC20 and/or a consensus RSV M2-1 protein or immunogenic fragment thereof are also disclosed. Immunomodulatory methods and methods of inducing an immune response against RSV are disclosed. Method of preventing RSV infection and methods of treating individuals infected with RSV are disclosed. | 03-19-2015 |
20150079122 | HUMAN ROTAVIRUS VACCINE STRAINS AND DIAGNOSTICS - A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine. | 03-19-2015 |
20150086577 | PATHOGENIC PHLEBOVIRUS ISOLATES AND COMPOSITIONS AND METHODS OF USE - Described herein are the clinical and laboratory characteristics of two patients bitten by ticks and infected with a unique member of the genus Phlebovirus (family Bunyaviridae) with a proposed name of Heartland virus (HRTLV). Provided herein are nucleotide and amino acid sequences of the Phlebovirus isolates, primers and probes that specifically hybridize with the Phlebovirus isolates, and antibodies specific for the Phlebovirus proteins. Also provided are detection assays using the Phlebovirus nucleic acid molecules, proteins, probes, primers and antibodies. Further provided are recombinant Phleboviruses and their use for eliciting an immune response in a subject. | 03-26-2015 |
20150086578 | HUMAN CYTOMEGALOVIRUS VACCINE - Combination peptides, polypeptides and proteins that elicit high titer neutralizing antibodies against cytomegalovirus (CMV) are provided. The combination peptides, polypeptides and proteins encompass epitopes located within the UL130 and UL131 components of the gH/gL/UL128-131 protein complex, in particular, epitopes located within amino acid residues 27-46 of UL130 and amino acid residues 90-106 of UL131. The combination peptides, polypeptides and proteins, and the nucleic acids encoding them, may be used in vaccines, and as diagnostic and research tools. | 03-26-2015 |
20150086579 | ADENOVIRAL-BASED VECTORS - The present invention provides replication competent adenoviral vectors capable of expressing antigens from infectious pathogens, such as influenza virus. The adenoviral vectors can be used to vaccinate subjects against the infectious pathogens. The adenoviral vectors comprise heterologous sequences encoding the antigens. The heterologous sequences can be inserted into various locations in the adenoviral vectors, including in or near specific E3 deletions and/or integrated into the adenoviral hexon coding region. The adenoviral vectors can be derived from any adenoviral serotype, particularly an Ad4 or Ad7 serotype. | 03-26-2015 |
20150093403 | CANINE CIRCOVIRUS SEQUENCES AND USES THEREOF - The invention is directed to a isolated a canine circoviruses associated with canine respiratory and gastrointestinal disease, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to antibodies against antigens from canine circoviruses. The invention also relates to iRNAs which target nucleic acid sequences of the canine circovirus. The invention is related to methods for detecting the presence or absence of canine circoviruses in an animal. The invention is also related to immunogenic compositions for inducing an immune response against canine circoviruses in an animal. | 04-02-2015 |
20150093404 | PCV2 ORF2 PROTEIN VARIANT AND VIRUS LIKE PARTICLES COMPOSED THEREOF - Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation. | 04-02-2015 |
20150093405 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 04-02-2015 |
20150093406 | Modified Coiled Coil Type Proteins having Improved Properties - The present application is related to a modified protein comprising a protein having a coiled coil domain and a peptide having the sequence such as shown in SEQ ID NO 1: ZXBBBBZ that is linked to the coiled coil domain wherein:
| 04-02-2015 |
20150098958 | Influenza Nucleoprotein Vaccines - The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from Influenza strain A, B or C, and a variant of a C4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from Influenza. The invention is also related to nucleic acids, vectors, fusion proteins and immunogenic compositions, for their use as a vaccine or immunotherapy for the prevention and treatment of influenza disease. | 04-09-2015 |
20150098959 | Mucosal Immunity-Stimulating Agent, and Oral Pharmaceutical Composition for Treating HPV Infection - A mucosal immunity-stimulating agent contains a Kampo preparation having a revitalizing activity and a mucosal adjuvant. An oral pharmaceutical composition for treating HPV infection contains at least HPV E7 polypeptide and a Kampo preparation having a revitalizing activity. | 04-09-2015 |
20150104475 | COMPOSITIONS AND METHODS RELATED TO VIRAL VACCINES - Provided herein are methods and compositions relating to Infectious Bursal Disease Virus (IBDV), and vaccines for treatment and prevention thereof. | 04-16-2015 |
20150104476 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention. | 04-16-2015 |
20150110822 | ONCOLYTIC HERPES SIMPLEX VIRUS AND THERAPEUTIC USES THEREOF - The present invention relates to variants of herpes simplex virus (HSV) that selectively infect and replicate in cancer cells, including HSV strains that selectively infect and replicate in bladder cancer cells. Preferred HSV of the invention have intact endogenous Us11 and Us12 genes and have genes encoding ICP34.5 replaced with a gene encoding Us11 fused to an HSV immediate early (IE) promoter. The variant HSV of the invention also comprise one or more additional heterologous genes encoding immunomodulatory polypeptides. Methods and compositions using these variant HSV, e.g., for treating cancer in a subject, are also provided. | 04-23-2015 |
20150110823 | PARTICULATE VACCINE FORMULATIONS - The present disclosure provides vaccine formulations comprising at least one peptide antigen assembly and at least one adjuvant. The disclosure also provides methods of inducing an immune response in a mammal and methods of treating a disease in a mammal utilizing the vaccine formulations. | 04-23-2015 |
20150110824 | METHOD OF VACCINATION AGAINST HUMAN PAPILLOMAVIRUS - The disclosure provides immunogenic compositions comprising HPV VLPs from one or more HPV types in combination with an adjuvant comprising a TLR agonist for use in a method for the prevention of HPV infection or disease in an individual, wherein a first dose of the immunogenic composition comprising HPV VLPs and a TLR agonist, is administered followed by a second dose of an immunogenic composition comprising HPV VLPs from one or more HPV types but which does not comprise a TLR agonist. | 04-23-2015 |
20150110825 | SELF-ASSEMBLED NANOPARTICLE VACCINES - The present invention provides nanoparticles and compositions of various constructs that combine meta-stable viral proteins (e.g., RSV F protein) and self-assembling molecules (e.g., ferritin, HSPs) such that the pre-fusion conformational state of these key viral proteins is preserved (and locked) along with the protein self-assembling into a polyhedral shape, thereby creating nanoparticles that are effective vaccine agents. The invention also provides nanoparticles comprising a viral fusion protein, or fragment or variant thereof, and a self-assembling molecule, and immunogenic and vaccine compositions including the same. | 04-23-2015 |
20150110826 | Production of Heterologous Polypeptides in Microalgae, Microalgal Extracellular Bodies, Compositions, and Methods of Making and Uses Thereof - The present invention relates to recombinant microalgal cells and their use in heterologous protein production, methods of production of heterologous polypeptides in microalgal extracellular bodies, microalgal extracellular bodies comprising heterologous polypeptides, and compositions comprising the same. | 04-23-2015 |
20150110827 | FUSION PROTEINS AND METHODS OF USE - Compositions that include at least three fusion proteins comprising flagellin and influenza antigens. In embodiments, the influenza antigens can include influenza A and influenza B antigens. The composition can further include at least one adjuvant. | 04-23-2015 |
20150125479 | ANTIBODIES AGAINST AND METHODS FOR PRODUCING VACCINES FOR RESPIRATORY SYNCYTIAL VIRUS - The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection. | 05-07-2015 |
20150125480 | METHODS FOR CONSTRUCTING ANTIBIOTIC RESISTANCE FREE VACCINES - The present invention provides | 05-07-2015 |
20150132330 | INFLUENZA VIRUS VACCINES AND USES THEREOF - Provided herein are flu hemagglutinin polypeptides, including chimeric influenza virus hemagglutinin polypeptides, and flu hemagglutinin polypeptides comprising modified glycosylation sites and non-naturally glycosylation sites, compositions comprising the same, vaccines comprising the same and methods of their use. | 05-14-2015 |
20150132331 | Influenza Vaccine Constructs - Vaccine compositions and methods of producing and using the same are provided, which compositions comprise a modified HA stem domain in a trimeric configuration. | 05-14-2015 |
20150140025 | HERPES SIMPLEX VIRUS VACCINE - Herpes Simplex Virus (HSV) antigens that elicit an HSV-specific immune response and can be used to treat or prevent HSV infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against HSV, treat or prevent HSV disease, induce a T cell response against HSV, and induce an antibody response against HSV also are provided. | 05-21-2015 |
20150291664 | BIOTINYLATED PROTEIN - The present invention relates to a fused protein. In particular, it relates to biotinylated protein comprising a protein selected from a group consisting of flavivirus structural and non-structural (NS) proteins. | 10-15-2015 |
20150297709 | Porcine Circovirus Type 2 (PCV2), Immunogenic Composition Containing the Same, Test Kit, and Application Thereof - The invention relates to a novel porcine circovirus type 2 (PCV2) strain. The invention also relates to immunogenic compositions containing the novel PCV2 strain, PCV2 test kits, and applications of the novel PCV2 strain. | 10-22-2015 |
20150299290 | IMMUNOGENIC VACCINE - A glycolipopeptide comprising a carbohydrate component, a lipid component, and a MUC1 peptide component that induces both a humoral and a cellular immune response for use as a therapeutic or prophylactic vaccine. | 10-22-2015 |
20150306202 | ATTENUATED LIVE VACCINE FOR CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS AND ERVE VIRUS - The genetically modified nairoviruses of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Exemplary are Crimean-Congo hemorrhagic fever virus and Erve virus. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent for prophylaxis and treatment. | 10-29-2015 |
20150306203 | SYNTHETIC PEPTIDE-BASED EMERGENCY VACCINE AGAINST FOOT AND MOUTH DISEASE (FMD) - Synthetic FMD peptide immunogens and compositions containing the same are disclosed. Methods for detecting, treating, and preventing an FMD infection in an animal using the synthetic FMD peptide immunogens are also disclosed. In a specific embodiment, a peptide-based emergency vaccine and formulations thereof against Foot and Mouth Disease is described. Various vaccine formulations contain a mixture of peptides derived from FMDV VP1 protein; each peptide containing a B cell FMDV neutralizing/receptor binding epitope sequence linked to an artificial Th epitope to enhance the immunogenicity of each peptide. Disclosed vaccine formulations containing viral immunogens can optionally be supplemented with a mixture of peptides representing the FMDV endogenous Th epitopes derived from FMDV proteins, homologues and functional analogues thereof. Such viral peptide compositions are prepared in an acceptable delivery system as vaccine formulations and can provide protection pigs and cattle from infection upon FMDV challenge with only single administration. | 10-29-2015 |
20150306207 | RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 10-29-2015 |
20150306208 | Soluble Forms of Hendra and Nipah Virus G Glycoprotein - This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses. | 10-29-2015 |
20150306209 | CANINE PARVOVIRUS TYPE 2c ISOLATES AND METHODS OF USE - The present invention discloses an attenuated canine parvovirus. In addition, the present invention discloses isolated and/or recombinant canine parvovirus capsid proteins and the nucleic acids that encode the canine parvovirus capsid proteins. The present invention further discloses immunogenic compositions and/or vaccines comprising the attenuated canine parvovirus isolates, corresponding capsid proteins, and/or recombinant vectors which express nucleic acids that encode the canine parvovirus capsid proteins. | 10-29-2015 |
20150306210 | VACCINE AGAINST BETA-HERPESVIRUS INFECTION AND USE THEREOF - The present invention is related to a beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient. | 10-29-2015 |
20150313987 | Low Antigen-dose Immunization for Maximizing T-helper Cell 1 (Th1) Immunity Against a Pathogen - Disclosed are compositions, kits, and methods for inducing an immune response against disease. The dosage of antigen contained or utilized in the presently disclosed compositions, kits, and methods is substantially lower than dosages conventionally used in the field. The compositions, kits, and methods may be utilized to induce a cell-mediated response, such as a T-helper cell response, and/or a humoral response against a pathogen or a disease. In some embodiments, the compositions, kits, and methods may be utilized to induce preferentially a Th1 response versus other types of immune responses such as a Th2 response. | 11-05-2015 |
20150315548 | INFLUENZA VIRUS REASSORTMENT - New influenza donor strains for the production of reassortant influenza A viruses are provided. | 11-05-2015 |
20150320853 | EFFECTIVE METHOD OF TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS - The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and | 11-12-2015 |
20150328303 | Methods and Compositions for Dengue Virus Epitopes - The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce a dengue virus E glycoprotein domain I and domain II hinge region from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone. | 11-19-2015 |
20150328304 | DENGUE VIRUS VACCINE COMPOSITION - Vaccine compositions that comprise at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The vaccine composition that comprises a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype, together with the oligonucleotide identified as SEQ ID NO 1, gives rise to higher levels of cellular immune response and protection in mice as compared with that produced by formulations of the same antigen together with oligonucleotides with potential adjuvant capacity which were reported previously. The efficacy of the compositions that comprise the SEQ ID NO 1 oligonucleotide has been demonstrated in non-human primates. These compositions may be monovalent, bivalent or tetravalent and are combined in different immunization regimes with a view to inducing a functional immune response to the four viral serotypes. | 11-19-2015 |
20150328306 | ANTIBODIES AGAINST AND METHODS FOR PRODUCING VACCINES FOR RESPIRATORY SYNCYTIAL VIRUS - The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection. | 11-19-2015 |
20150328307 | Recombinant Spike Protein Subunit Based Vaccine for Porcine Epidemic Diarrhea Virus (PEDV) - The present invention encompasses porcine epidemic diarrhea virus (PEDV) vaccines or compositions. The vaccine or composition may be a vaccine or composition containing PEDV antigens. The invention also encompasses recombinant vectors encoding and expressing PEDV antigens, epitopes or immunogens which can be used to protect porcine animals against PEDV. | 11-19-2015 |
20150329597 | RSV F PREFUSION TRIMERS - Complexes that contain RSV F ectodomain polypeptides and methods for making the complexes are disclosed. The RSV F ectodomain polypeptides can be in the prefusion form. | 11-19-2015 |
20150335726 | Filovirus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using Same - Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus filovirus immunogen including a consensus Marburgvirus filovirus glycoprotein MARV GP immunogen, a consensus Ebolavirus Sudan filovirus glycoprotein SEBOV GP immunogen and a consensus Ebolavirus Zaire glycoprotein ZEBOV GP immunogen are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide. Immunomodulatory methods and methods of inducing an immune response against filovirus, particularly Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire are disclosed. Method of preventing filovirus infection, particularly infection by Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire and methods of treating individuals infected with filovirus infection, particularly infection by Marburgvirus, Ebolavirus Sudan and Ebolavirus Zaire are disclosed. Consensus filovirus proteins are disclosed. | 11-26-2015 |
20150335729 | INFLUENZA VIRUS VACCINES AND USES THEREOF - Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use. | 11-26-2015 |
20150335730 | RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 11-26-2015 |
20150335733 | Immunogenic Composition and Methods of Using the Compositions for Inducing Humoral and Cellular Immune Responses - Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject an immune response that includes a humoral immune response and cellular immune response, both CD4 and CD8 T lymphocyte immune responses, thereby providing a complete adaptive immune response to one or more antigens. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of both a humoral immune response and cellular immune response is desired and beneficial. | 11-26-2015 |
20150335734 | ANTIGENIC PEPTIDE OF HSV-2 AND METHODS FOR USING SAME - The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 11-26-2015 |
20150352202 | BROADLY REACTIVE MOSAIC PEPTIDE FOR INFLUENZA VACCINE - The invention provides for mosaic influenza virus HA and NA sequences and uses thereof. | 12-10-2015 |
20150361141 | CRIMEAN-CONGO HAEMORRHAGIC FEVER VIRUS ANTIGENIC COMPOSITION - The present invention provides a viral vector or bacterial vector, said vector comprising a nucleic acid sequence encoding a Crimean-Congo Haemorrhagic Fever Virus (CCHFV) glycoprotein or antigenic fragment thereof; wherein said vector is capable of inducing an immune response in a subject. The present invention also provides compositions and uses of the vector in methods of medical treatment. | 12-17-2015 |
20150366960 | RESPIRATORY SYNCYTIAL VIRUS F PROTIEN EPITOPES - Respiratory Syncytial Virus is a common cold virus belonging to the family of paramyxovirus. RSV is virulent, easily transmissible and the most common cause of lower respiratory tract disease in children of less than 2 years of age. Up to 98% of children attending day care will be infected in a single RSV season. Between 0.5% and 3.2% of children with RSV infection require hospitalization. Approximately 90,000 hospital admissions and 4500 deaths per year were reported in United States. Major risk factors for hospitalization due to RSV are premature birth, chronic lung disease, congenital heart disease, compromised immunity, and age younger than 6 weeks in otherwise healthy children. | 12-24-2015 |
20150368621 | MUTATIONS THAT CONFER GENETIC STABILITY TO ADDITIONAL GENES IN INFLUENZA VIRUSES - The disclosure provides for an isolated recombinant influenza virus having at least one of: a PA gene segment encoding PA with a residue at position 443 that is not arginine, a PB1 gene segment encoding PB1 with a residue at position 737 that is not lysine, a PB2 gene segment encoding PB2 with a residue at position 25 that is not valine or a residue at position 712 that is not glutamic acid, a NS gene segment encoding a NS1 with a residue at position 167 that is not proline, a HA gene segment encoding a HA with a residue at position 380 that is not threonine, or any combination thereof, and methods of making and using the virus. | 12-24-2015 |
20150374814 | Polyvalent Fusion Protein Vaccine Against Influenza - The problem to be solved: absence of safe efficient universal vaccine against influenza. The solution: The vaccine based on the fusion protein consisting of antigenic determinants of haemagglutinins of influenza A and B viruses and flagellin fragments functioning as safe adjuvant (SEQ ID NO:1) joined via flexible hinges is given which can be used for prophylaxis of influenza caused by existing influenza A and B strains as well as by possible reassortants. Safety, efficacy, polyvalence and preventive effect have been demonstrated. Usage of the present vaccine will allow to provide a universal protection against influenza. | 12-31-2015 |
20150374815 | METHODS AND COMPOSITIONS FOR TREATMENT WITH SYNTHETIC NANOCARRIERS AND IMMUNE CHECKPOINT INHIBITORS - Disclosed are synthetic nanocarrier compositions and immune checkpoint inhibitor compositions and related methods for administration to a subject. | 12-31-2015 |
20160000897 | RECOMBINANT ANTIGENS OF PORCINE CIRCOVIRUS 2 (PCV-2) FOR VACCINE FORMULATIONS, DIAGNOSTIC KIT AND USE THEREOF - The present invention relates to the preparation of the recombinant antigen of the viral capsid of | 01-07-2016 |
20160000900 | OLIGOMERIC INFLUENZA IMMUNOGENIC COMPOSITIONS - Embodiments are provided for network resource allocation considering user experience, satisfaction, and operator interest. An embodiment method by a network component for allocating network resources includes evaluating, for a user, a QoE for each flow of a plurality of flows in network traffic in according with a QoE model, and further evaluating, for an operator, a revenue associated with the flows in accordance with a revenue model. A plurality of priorities that correspond to the flows are calculated in accordance with the QoE for the user and the revenue for the operator. The method further includes identifying a flow of the flows with a highest value of the priorities, and allocating a network resource for the flow. In an embodiment, the QoE model is a satisfaction model that provides a measure of user satisfaction for each flow in accordance with a subscription or behavior class of the user. | 01-07-2016 |
20160008453 | MOLECULAR ANTIGEN ARRAY | 01-14-2016 |
20160008456 | FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS) | 01-14-2016 |
20160008457 | Inactivated Vaccine for Porcine Epidemic Diarrhea Virus (PEDV) | 01-14-2016 |
20160015799 | RECOMBINANT ANTIGENS OF THE PORCINE CIRCOVIRUS 2 (PCV-2) FOR VACCINE FORMULATIONS AND USE THEREOF - The present continuation-in-part of the Application BR 7 10 2013 001893 refers to the obtainment of the viral capsid recombinant antigen of the Porcine circovirus 2 (PCV-2) and modifications thereof, upon expression in prokaryotic system, recovery of virus-like particles (VLPs) and its use in vaccine formulations. The antigens and vaccine formulations can be used in the immunization of animals in control programs of the diseases associated with PCV-2 in conventional swine production systems and represent alternatives to vaccines available on the market. | 01-21-2016 |
20160015801 | RECOMBINANT GALLID HERPESVIRUS 3 (MDV SEROTYPE 2) VECTORS EXPRESSING ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF - The present invention provides recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain and express antigens of avian pathogens, recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain a mutated gC gene, compositions comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors, polyvalent vaccines comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant Gallid herpesvirus 3 (MDV-2) vectors. | 01-21-2016 |
20160022804 | Immunogenic Human Rhinovirus (HRV) Compositions - Novel compositions useful as human rhino virus immunogens are provided. The compositions enable a host response to sites normally not recognized by a host. | 01-28-2016 |
20160022805 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR HUMAN AND AVIAN H5N1 INFLUENZA - Described herein is the generation of optimized H5N 1 influenza HA polypeptides for eliciting a broadly reactive immune response to H5N1 influenza virus isolates. The optimized HA polypeptides were developed through a series of HA protein alignments, and subsequent generation of consensus sequences, based on human and avian H5N1 isolates. Provided herein are optimized H5N1 HA polypeptides, and compositions, fusion proteins and VLPs comprising the HA polypeptides. Further provided are codon-optimized nucleic acid sequences encoding the HA polypeptides. Methods of eliciting an immune response against influenza virus in a subject are also provided by the present disclosure. | 01-28-2016 |
20160022806 | Influenza Nucleic Acid Molecules And Vaccines Made Therefrom - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin and/or influenza B hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza A serotypes and/or influenza B serotypes, or combinations thereof, using the vaccines that are provided. | 01-28-2016 |
20160024156 | ANTIVIRAL VACCINES WITH IMPROVED CELLULAR IMMUNOGENICITY - The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects. | 01-28-2016 |
20160030547 | SWINE INFLUENZA VIRUSES AND CONSTRUCTS AND USES THEREOF - Disclosed are compositions and methods comprising vectors and a reverse genetics competent unit comprising one or more recombinant influenza viruses. Recombinant influenza viruses comprising swine RNA polymerase I promoter are disclosed. Constructs comprising swine RNA polymerase I promoter nucleic acid sequences are also provided. Methods of inducing protecting immunity with the recombinant influenza viruses are disclosed. In certain embodiments, the reverse genetics competent unit comprises pathogenic units necessary for producing pathogens de novo from a nucleotide-based vector for influenza virus in swine. | 02-04-2016 |
20160030548 | Influenza Nucleic Acid Molecules And Vaccines Made Therefrom - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotpyes using the vaccines that are provided. | 02-04-2016 |
20160031946 | MULTI-EPITOPIC VACCINE - The present invention relates to isolated polypeptides comprising: (i) a protein transduction domain consisting of ZEBRA or a fragment thereof that retains the capacity of internalization, (ii) at least one CD4 | 02-04-2016 |
20160031991 | TARGETING VACCINES FOR VETERINARY USE - The present invention relates to therapeutic compounds, such as vaccines against avian diseases and in particular to DNA vaccines. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a DNA vaccine or used separately. Further described are pharmaceutical formulations, host cells and methods for producing the vaccines, as well as methods for the treatment or prevention of various diseases in animals, such as avians, such as cancers and infectious diseases. | 02-04-2016 |
20160032253 | ATTENUATION OF INFECTIOUS BRONCHITIS VIRUS VARIANT GA-13 - The present invention provides the isolation and characterization of a new infectious bronchitis virus (IBV) variant, the IBV GA-13 variant, and the production of attenuated isolates thereof, including, but not limited to, the attenuated IBV GA13 isolate 103505 Kd E86, and the use of such IBV isolates in materials and methods for combating infectious bronchitis virus in poultry and reducing the economic impact that infectious bronchitis disease has on poultry production. | 02-04-2016 |
20160038583 | INFLUENZA HEMAGGLUTININ VARIANTS AND USES THEREFOR - The present invention features polynucleotides encoding hemagglutinin (HA) polypeptide variants of a wild-type A/Anhui/1/2013 HA polypeptide, H7N9 influenza A viruses comprising such modified HA polynucleotides, methods of growing such viruses, and immunogenic compositions comprising such polynucleotides. | 02-11-2016 |
20160038586 | Virus-like Particle Vaccines - The invention is directed to dimeric fusion proteins and virus-like particles comprising such dimeric fusion proteins. These dimeric fusion proteins comprise an antigen or antigenic fragment carried between two viral structural proteins or fragments thereof, with or without linkers, in a manner that, relative to traditional monomeric platforms, minimizes steric hindrance among the antigen or antigenic fragment and the viral structural proteins or fragments thereof. This novel design provides for multivalent vaccines and enhanced immunogenicity. The invention also relates to nucleic acids encoding such dimeric fusion proteins and host cells comprising such nucleic acids. The invention further relates to pharmaceutical compositions comprising the dimeric fusion proteins and/or virus-like particles of the invention, and methods of prevention or treatment using such compositions. | 02-11-2016 |
20160040134 | VIRUS LIKE PARTICLE COMPRISING MODIFIED ENVELOPE PROTEIN E3 - A virus like particle comprising a viral structural protein which comprises modified envelope protein E3. The viral structural protein may be that derived from or alphavirus or flavivirus. Especially, the viral structural protein may be derived from Chikungunya virus or Venezuelan equine encephalitis virus. | 02-11-2016 |
20160045589 | Foot and Mouth Disease Virus (FMDV) Consensus Proteins, Coding Sequences Therefor and Vaccines Made Therefrom - The present invention relates to synthetic, consensus foot-and-mouth disease virus (FMDV) immunogenic proteins and nucleic acid molecule encoding such proteins, to vaccines against FMDV, to methods for inducing immune responses against FMVD, to methods for distinguishing between individuals infected with FMDV versus those vaccinated against FMDV, and methods of prophylactically and/or therapeutically immunizing individuals against FMDV. | 02-18-2016 |
20160046675 | PREFUSION RSV F PROTEINS AND THEIR USE - Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject. | 02-18-2016 |
20160051660 | METHODS OF PRODUCING INFLUENZA VACCINE COMPOSITIONS - Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided. | 02-25-2016 |
20160051661 | FLUOROCARBON-LINKED PEPTIDE FORMULATION - The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles. | 02-25-2016 |
20160051662 | H3 INFLUENZA A VIRUS - The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof. | 02-25-2016 |
20160052973 | Stabilised FMDV Capsids - The present invention relates to the stabilisation of foot-and-mouth disease virus (FMDV) capsids, by specific substitution of amino acids in a specific region of FMDV VP2. The invention provides stabilised FMDV capsids and vaccines against FMD. | 02-25-2016 |
20160060303 | MUTANT SPIKE PROTEIN EXTENDING THE TISSUE TROPISM OF INFECTIOUS BRONCHITIS VIRUS (IBV) - The present invention provides an infectious bronchitis virus (IBV) spike protein (S protein) which is based on an S protein from an IBV strain with restricted tissue tropism, but which comprises the sequence XBBXBX in the part of the S2 protein corresponding to residues 686 to 691 of the sequence given as SEQ ID No. 2, where B is a basic residue and X is any amino acid; and which comprises at least one of the following amino acid substitutions with reference to the position numbering of SEQ ID NO:2: Leucine (L) to Phenylalanine (F) at position 578 Asparagine (N) to Serine (S) at position 617 Asparagine (N) to Serine (S) at position 826 Leucine (L) to Phenylalanine (F) at position 857 and Isoleucine (I) to Valine (V) at position 1000 such that an IBV virus comprising the S protein has extended tissue tropism. The present invention also provides a virus comprising such an S protein. | 03-03-2016 |
20160067328 | RECOMBINANT NEURAMINIDASE AND USES THEREOF - A recombinant neuraminidase based on amino acid sequence (SEQ ID NO: 1) of wild-type pH1N1-NA (A/Texas/05/2009) influenza virus is provided. The recombinant neuraminidase of the present invention has an ectodomain with an amino acid sequence essentially identical to SEQ ID NO: 1 and replaced at specific positions 149, 344, 365 and 366 residue(s) with corresponding amino acids of other influenza viruses. The recombinant neuraminidase may incur cross-protective immunity and be used as universal influenza vaccine. | 03-10-2016 |
20160067330 | HERPES VIRUS VACCINES AND TREATMENTS - Provided herein are vaccine compositions and methods of their use in treating or preventing Herpes diseases. | 03-10-2016 |
20160068575 | NOVEL RECOMBINANT BACULOVIRUS VECTOR AND USES THEREOF - Disclosed herein is a recombinant viral construct and its uses thereof. The recombinant viral construct is capable of simultaneously expressing three exogenous proteins, including a classical swine fever virus (CSFV) antigen, a porcine | 03-10-2016 |
20160074500 | INFECTIOUS DNA VACCINES AGAINST CHIKUNGUNYA VIRUS - Described herein are i-DNA™ vectors and vaccines and methods for using the same. The i-DNA™ generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly chikungunya virus (CHIKV). When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus. | 03-17-2016 |
20160074502 | RECOMBINANT SUBUNIT DENGUE VIRUS VACCINE - The present invention provides dengue virus vaccines and immunogenic compositions for administration to human subjects. The vaccine compositions of the present invention comprise recombinantly produced monomeric and/or dimeric forms of truncated dengue virus envelope glycoprotein that, when formulated together with an adjuvant and a pharmaceutically acceptable carrier, induce balanced tetravalent immune responses. In preferred embodiments of the compositions described herein, the DEN4 protein component is a dimeric form of DEN4. The compositions are designed to be acceptable for use in the general population, including immunosuppressed, immunocompromised, and immunosenescent individuals. Also provided herein are methods of inducing a protective immune response in a human patient population by administering the compositions described herein to the patients. | 03-17-2016 |
20160074503 | Porcine Reproductive and Respiratory Syndrome Virus Compositions and Uses Thereof - Provided herein are embodiments relating to porcine reproductive and respiratory syndrome (PRRS) virus, compositions comprising the virus, and methods of using the virus. The virus may be used to immunize a mammal, including swine. Methods for generating an immune response against PRRS virus in swine by administering a composition comprising the virus are provided. | 03-17-2016 |
20160075742 | HUMAN ADAPTATION OF H3 INFLUENZA - The present invention provides, among other things, technologies and methodologies for detection, treatment, and/or prevention of influenza transmission and/or infection. The present invention also provides technologies for monitoring influenza variants for their potential to present a pandemic risk to humans. | 03-17-2016 |
20160083698 | LONE STAR VIRUS - This disclosure concerns the isolation, identification and sequencing of a unique | 03-24-2016 |
20160090601 | Production of Polypeptides Relevant to Human and Animal Health Using Yarrowia lipolytica - The present invention relates to the expression of polypeptides using | 03-31-2016 |
20160095915 | INTERACTIONS OF BETANODAVIRUSES IN INFECTION - Disclosed are interactions between different betanodaviruses during infection of cells “in vitro” and in European sea bass. More specifically, fish administered striped jack nervous necrosis viruses (SJNNV), which are then exposed to red-spotted grouper nervous necrosis viruses (RGNNV), have fewer symptoms of disease associated with RGNNV and/or increased survival as compared to fish not administered SJNNV prior to exposure to RGNNV. | 04-07-2016 |
20160095916 | INDUCTION OF CROSS-REACTIVE CELLULAR RESPONSE AGAINST RHINOVIRUS ANTIGENS - The present invention concerns: a) an isolated peptide comprising an amino acid sequence which is at least 90% identical to the VP4 amino acid sequence of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and/or b) an isolated peptide comprising an amino acid sequence of at least 100 amino acids which is at least 90% identical to an amino acid sequence located in the last 363 C-terminal amino acids of the RNA polymerase of a rhinovirus, or an isolated polynucleotide comprising a nucleic acid sequence encoding said peptide, placed under the control of the elements necessary for its expression in a mammalian cell; and c) a Th1 adjuvant when said immunogenic composition comprises one or more of said isolated peptides. | 04-07-2016 |
20160095918 | RAPID, EFFICIENT PURIFICATION OF HSV-SPECIFIC T-LYMPHOCYTES AND HSV ANTIGENS IDENTIFIED VIA SAME - A method of identifying an immunologically active antigen of a virus that attacks skin, as well as a method of enriching a population of lymphocytes for T lymphocytes that are specific to a virus that attacks skin. Also provided are HSV antigens and epitopes that are useful for the prevention and treatment of HSV infection that have been identified via the methods of the invention. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 04-07-2016 |
20160102123 | STABILIZED SOLUBLE PREFUSION RSV F POLYPEPTIDES - Described are stable pre-fusion respiratory syncitial virus (RSV) F polypeptides, immunogenic compositions comprising the polypeptides and uses thereof for the prevention and/or treatment of RSV infection. | 04-14-2016 |
20160106828 | ADAPTATION OF ATTENUATED INFECTIOUS BRONCHITIS VIRUS (IBV) TO EMBRYONIC KIDNEY CELLS AND VACCINE THEREBY PRODUCED - Disclosed are methods for preparing a vaccine against infection by infectious bronchitis virus (IBV). The methods typically include passing a heterogeneous attenuated population of IBV in chicken embryonic kidney cells, and optionally may include further passaging the heterogeneous attenuated population of IBV in embryonated chicken eggs (ECE) in order to obtain passaged attenuated population of IBV. Also disclosed are passaged attenuated populations of IBV in which the populations display a desired degree of homogeneity. Also disclosed are vaccines comprising the passaged attenuated populations of IBV and methods of vaccination comprising administering the disclosed vaccines. | 04-21-2016 |
20160114025 | COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES - Provided herein are | 04-28-2016 |
20160114029 | PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION AND PREPARATION METHOD AND USE THEREOF - Provided in the embodiments of the present invention is a vaccine composition including an immune amount of attenuated live vaccine, inactivated vaccine, subunit vaccine, synthetic vaccine, or genetically engineered vaccine of the porcine pseudorabies virus strain. The vaccine composition can effectively induce antibody generation, and prevent infections of virulent strains of the porcine pseudorabies virus, and provides effective protection for pigs. | 04-28-2016 |
20160122396 | THERAPEUTIC HPV16 VACCINES - Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV16. | 05-05-2016 |
20160122397 | REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY AND LETHALITY IN INFLUENZA - The present invention provides methods of differentiating the infectivity and lethality of isolates of influenza virus and provides compounds for diagnosing, preventing, and treating outbreaks of influenza virus including compounds for diagnosing, preventing, and treating across different strains of influenza virus. | 05-05-2016 |
20160122398 | RECOMBINANT RSV ANTIGENS - This disclosure provides recombinant respiratory syncytial virus (RSV) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of RSV infection. | 05-05-2016 |
20160130305 | DENGUE VIRUS (DV) POLYPEPTIDE SEQUENCES, T CELL EPITOPES AND METHODS AND USES THEREOF - Dengue virus (DV) peptides, including T cell epitopes, structural and non-structural (NS) polypeptide sequences, subsequences and modifications thereof, nucleotide sequences encoding such peptides, and compositions including such peptides and encoding nucleotide sequences, and cells expressing such peptides, are provided. Such DV peptides, nucleotide sequences and compositions, can be used to elicit, stimulate, induce, promote, increase, enhance or activate an anti-DV CD8 | 05-12-2016 |
20160130308 | Nucleic Acid Molecules Encoding Novel Herpes Antigens, Vaccine Comprising The Same, And Methods Of Use Thereof - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of herpes virus antigens, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provide herein are methods for generating an immune response against herpes virus using the vaccines that are provided. | 05-12-2016 |
20160136262 | INFLUENZA VIRUS VACCINES AND USES THEREOF - Provided are influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA | 05-19-2016 |
20160151477 | DENGUE VIRUS VACCINE COMPOSITIONS AND METHODS OF USE THEREOF | 06-02-2016 |
20160151478 | Novel Flavivirus Antigens | 06-02-2016 |
20160151480 | Universal Influenza Vaccine | 06-02-2016 |
20160158340 | INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX PROTEINS - An immunological composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in call culture rather than eggs. The matrix protein may be a fragment of a full-length viral matrix protein e.g., a matrix M1 fragment with a molecular weight of less than 20 kDa. The composition may be a subunit vaccine comprising purified surface glycoproteins. | 06-09-2016 |
20160158342 | VACCINES FOR DISEASES CAUSED BY VIRUSES OF THE FAMILY OF REOVIRIDAE - The invention relates to methods for producing a propagation-competent strain of a mutant Reoviridae virus, and to a propagation-competent strain of a mutant Reoviridae virus that is obtainable by a method of the invention. The invention further relates to a propagation-competent strain of a mutant Reoviridae virus, comprising a deletion of a genetic region that is relevant for propagation of the virus, and to a vaccine, comprising a propagation-competent strain of a mutant Reoviridae virus. | 06-09-2016 |
20160158343 | RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE VECTORS - Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided. | 06-09-2016 |
20160159864 | COMPLEXES OF CYTOMEGALOVIRUS PROTEINS - This disclosure provides an isolated human cytomegalovirus (HCMV) membrane protein complex, wherein said complex comprises gH, gL and at least one more HCMV glycoprotein. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. The disclosure also provides processes for expressing and purifying said complexes, and subsequent uses of said complexes in immunogenic compositions and vaccines. | 06-09-2016 |
20160166675 | EV71 VIRUS-LIKE PARTICLES AND PREPARATION METHOD AND APPLICATION THEREOF | 06-16-2016 |
20160166676 | Use of Immune Suppressive Peptides as Adjuvants | 06-16-2016 |
20160166677 | COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR H1N1 INFLUENZA | 06-16-2016 |
20160168583 | Plant Produced Human Papillomavirus Pseudovirion | 06-16-2016 |
20160175426 | COMPOSITIONS FOR MUCUSAL DELIVERY, USEFUL FOR TREATING PAPILLOMAVIRUS INFECTIONS | 06-23-2016 |
20160175427 | Influenza Nucleic Acid Molecules And Vaccines Made Therefrom | 06-23-2016 |
20160176932 | STABILIZED SOLUBLE PRE-FUSION RSV F POLYPEPTIDES | 06-23-2016 |
20160193320 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS | 07-07-2016 |
20160193322 | COMBINATION IMMUNOGENIC COMPOSITIONS | 07-07-2016 |
20160193323 | Fowl Adenovirus Vaccine | 07-07-2016 |
20160199479 | T cell receptors | 07-14-2016 |
20160199481 | COMPOSITIONS AND METHODS FOR DIRECTED IMMUNOGEN EVOLUTION AND USES THEREOF | 07-14-2016 |
20160199482 | HENDRA AND NIPAH VIRUS G GLYCOPROTEIN IMMUNOGENIC COMPOSITIONS | 07-14-2016 |
20160199484 | Fowl Adenovirus Vaccine | 07-14-2016 |
20160200774 | PAPILLOMAVIRUS-LIKE PARTICLES (VLP) AS BROAD SPECTRUM HUMAN PAPILLOMAVIRUS (HPV) VACCINES | 07-14-2016 |
20160200775 | VIRUS LIKE PARTICLE COMPRISING MODIFIED ENVELOPE PROTEIN E3 | 07-14-2016 |
20160200776 | Truncated L1 Protein of Human Papillomavirus Type 58 | 07-14-2016 |
20160250315 | HUMAN PAPILLOMA VIRUS THERAPEUTIC VACCINE | 09-01-2016 |
20160250320 | IMMUNOREGULATORY PEPTIDES AND METHODS OF USE | 09-01-2016 |
20160250324 | VACCINE COMPOSITION COMPRISING AN IMMUNOGENIC PROTEIN AND COMBINATION ADJUVANTS FOR USE IN ELICITING ANTIGEN-SPECIFIC T-CELL RESPONSES | 09-01-2016 |
20160250325 | ADJUVANT COMPOUND | 09-01-2016 |
20160375122 | PRRSV minor protein-containing recombinant viral vectors and methods of making and use thereof - The present invention encompasses recombinant porcine reproductive and respiratory syndrome virus (PRRSV) vaccines or compositions. In particular, the invention encompasses recombinant adenovirus vectors encoding and expressing PRRSV gp2, gp3, gp4, gp5a, gp5 and/or E antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals from PRRSV. | 12-29-2016 |
20160375123 | DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES CONTAINING MUTATIONS THAT ELIMINATE IMMUNODOMINANT CROSS-REACTIVE EPITOPES - Described herein are dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes associated with immune enhancement. The disclosed dengue virus E-glycoproteins optionally further include mutations that introduce a strong CD4 T cell epitope. The disclosed E-glycoprotein polypeptides, or nucleic acid molecules encoding the polypeptides, can be used, for example, in monovalent or tetravalent vaccines against dengue virus. | 12-29-2016 |
20160375125 | THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR INFECTIOUS SALMON ANEMIA VIRUS - The present invention provides therapies, vaccines, and predictive methods for infectious salmon anemia virus and provides compounds for diagnosing, preventing, and treating outbreaks of infectious salmon anemia virus including compounds for diagnosing, preventing, and treating infectious salmon anemia across different strains of virus. | 12-29-2016 |
20160375126 | AGENTS THAT ENGAGE ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC-ASGPR) - The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells. | 12-29-2016 |
20170232094 | PORCINE CIRCOVIRUS TYPE 2 (PCV2) SUBUNIT VACCINE | 08-17-2017 |
20170232095 | FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS) | 08-17-2017 |
20170232098 | RECOMBINANT MUMPS VIRUS VACCINE | 08-17-2017 |
20170233450 | VIRUS LIKE PARTICLE COMPRISING PD-1 ANTIGEN OR PD-1 LIGAND ANTIGEN | 08-17-2017 |
20180021258 | NOVEL MULTIVALENT NANOPARTICLE-BASED VACCINES | 01-25-2018 |
20180021427 | H3 INFLUENZA A VIRUS | 01-25-2018 |
20180021428 | RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPS) | 01-25-2018 |
20190142951 | INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS | 05-16-2019 |
20190144831 | IMMORTALISED CHICKEN EMBRYONIC EPITHELIAL KIDNEY CELLS | 05-16-2019 |
20190144835 | DUCK ENTERITIS VIRUS AND THE USES THEREOF | 05-16-2019 |
20190144836 | DUCK ENTERITIS VIRUS AND THE USES THEREOF | 05-16-2019 |
20220133875 | METHODS FOR PREVENTING DISEASE OR DISORDER CAUSED BY RSV INFECTION - The present invention is generally related to modified or mutated respiratory syncytial virus (RSV) fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. Specifically, the disclosure provides a method of maternal immunization comprising administering a composition comprising an RSV F protein and an adjuvant to a pregnant woman carrying a gestational infant, wherein the method induces an immune response against at least one symptom associated with RSV lower respiratory tract infection (LRTI) in the infant following birth. | 05-05-2022 |
20220133878 | METHOD FOR THE SAFE INDUCTION OF IMMUNITY AGAINST RSV - Methods of inducing a safe immune response against respiratory syncytial virus (RSV) in a human subject in need thereof, including administering to the subject a composition including recombinant adenovirus including a nucleic acid encoding an RSV Fusion (F) protein including the amino acid sequence of SEQ ID NO: 1, and a pharmaceutically acceptable carrier, in a total dose of from about 1×101° to about 2×10″ viral particles (vp), are described. | 05-05-2022 |
20220135625 | SARS-COV-2 VIRUSES AND METHODS OF USE THEREOF - This invention relates to SARS-CoV-2 viruses adapted with nanoluciferase reporter molecules and mouse-adapted SARS-CoV-2 viruses, compositions including the same and methods of use thereof. | 05-05-2022 |